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Abstract 
 
Natural products and their derivatives have historically been an extremely valuable 
source for new entities in agriculture, pharmaceuticals and cosmeceuticals, to deliver 
a unique variety of structural templates for product development. Historically, 
terrestrial plants and microorganisms such as fungi and bacteria were the most 
important sources for biologically active natural products. The development of plant 
based products has some unique problems associated with the process, which can be 
best described as the "problem of supply" due to factors such as deforestation, 
environmental pollution, global warming and inability to synthesize due to structural 
complexity. The rediscovery of large numbers of previously reported compounds 
from terrestrial microbes contributes to the difficulties in discovering new structures. 
These problems necessitate the continuous search for novel and alternative bio 
resources, particularly those that can be produced at scale such as microorganisms. 
 
Since the middle of the last century, marine species and microorganisms have been 
explored as sources for the new chemical entity (NCEs). An advance in isolation and 
structure determination methods and equipment over the last thirty years has seen a 
rapid increase in the number of new structures identified. Nevertheless, marine 
chemical ecology and biodiversity are still relatively unexplored, with respect to the 
discovery of natural products, compared with terrestrial sources. Some 
researchers have specifically compared natural products from terrestrial and marine 
sources. They found that compounds from marine organisms generally exhibited a 
higher chemical novelty. In this Ph.D. the research aimed to isolate and characterize 
marine fungal secondary metabolite and evaluating their potential use in future 
cosmetic skin care products.  
 
The study begins with the collection of marine samples for the isolation of marine 
fungi. A range of marine samples were collected from diverse and unexplored marine 
habitats in India, which included beaches of Indian west coast and Andaman Island. 
All collected samples were subjected to isolation of marine fungi using a variety of 
techniques and culture conditions, as described in chapter 2. Seventy fungal strains 
were isolated from 60 marine samples. Among these 70 only 35 morphologically 
different stains were used in this research work. These 35 strains were analyzed for 
their optimum growth condition toward maximizing the production of secondary 
Abstract 
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metabolites using, by varying media conditions (salinity, nutrient strength, etc.). Of 
the result, full strength PDA media in artificial sea water was found to be best for 
90% of the fungal strains, in terms of their growth and production of secondary 
metabolites.  
   
All 35 strains were subjected to screening for antibacterial activity against eight 
human pathogenic bacteria, including Escherichia coli (MTCC-443), Pseudomonas 
aeruginosa (MTCC-424), Staphylococcus aureus (MTCC-96), Staphylococcus 
epidermidis (MTCC-3615), Micrococcus luteus (MTCC-106), Bacillus subtilis 
(MTCC-121), Bacillus megaterium (MTCC 1684) and Propionibacterium acnes 
(MTCC-1951). The crude extracts, prepared from 20 day fungal fermentation broth, 
were evaluated using agar well-diffusion and microdilution assays. Eight fungi were 
found to be most active and successfully classified as Simplicillium lamellicola (D 5), 
Emericellopsis minima (D 6), Leptosphaerulina sp. (AN 7), Penicillium citrinum 
(AN 10), Aspergillus aculeatus (AN 11), P. chrysogenum (AN 12), A. oryzae (G 3), 
A. sydowii (G 10).  The relevance of this screening was also confirmed by SEM 
analysis of the targeted bacteria before and after treatment with crude fungal extracts. 
Results show that the presence of active molecules in crude extracts causes damage 
to bacterial cell membranes. Marine isolate S. lamellicola (D 5) was the most active 
extract against both Gram-negative and Gram-positive bacteria, with a MIC value of 
1mg/ml. This promising strain was further exploited for the bioassay-guided 
fractionation and isolation of bioactive compounds. 
 
The aim of the next part of our investigation was the screening of marine fungi to 
search for potential tyrosinase inhibitors and antioxidants to control 
hyperpigmentation and photo aging of the skin. Fungal crude extracts were subjected 
for MBTH and DPPH radical scavenging assays for depigmentation and antioxidant 
potential, respectively. “Fungus P 2” was shown to be related to Talaromyces 
stipitatus and “Fungus D 4” was grouped with Aspergillus terreus. The PDA extracts 
of P2 and D4 showed antityrosinase activity (45%, 43%, respectively) at the lowest 
concentration 0.125 mg/mL. They also exhibited 94%, 97%, antioxidant activity, 
respectively, at a concentration of 0.500 mg/mL. Due to their bioactivity, these two 
fungi were selected for the future study. This is the first report of antityrosinase 
activity from T. stipitatus. 
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The final research aim of this study was the isolation and characterization of active 
antibacterial molecules present in the crude extract of marine fungi S. lamellicola (D 
5). Bioassay guided isolation was performed using TLC direct bioautography against 
S. epidermidis. One bioactive compound, 5, 6-dihydro-6-pentyl-5, 6-dihydropyran-2-
one (1), was isolated from the crude extract by chromatographic methods and 
characterized using LC-MS/MS analysis. Two additional compounds were 
tentatively identified as simplifungin (2) and a new derivative of halymecin G (3), by 
comparing LC-MS/MS data with that of reported metabolites from Simplicillium sp. 
The antibacterial activity of compound (1) has not previously been reported. 
 
Through this work, we have identified a marine fungal strain S. lamellicola (D 5) that 
is an efficient producer of antibacterial compounds against S. epidermidis. We also 
found that the marine fungi P 2 (Talaromyces stipitatus) and D 4 (Aspergillus 
terreus) are the potent producer of bioactive metabolites with antityrosinase and 
antioxidants activity.  
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1. Introduction  
 
Nature provides a diversity of pharmacologically active biomolecules. These natural 
biomolecules are important for the development of novel pharmaceuticals as well as 
cosmeceuticals. Between 1989-1995 around 60% of Food and Drug Administration 
(FDA) approved drugs and pre-NDA (New Drug Application) candidates were 
obtained from the natural environment (1). Natural products are obtained from both 
terrestrial and marine environments. Approximately 270,000 natural products have 
been discovered and some of them are in the market, either as medical drugs or in 
clinical use (2, 3).  
1.1. Marine natural products 
The marine ecosystem covers about 70% of the earth surface and is extraordinarily 
rich in biological diversity, particularly in tropical environments. According to the 
Global Biodiversity Assessment by the United Nations Environment Programme, 
oceans consist of 178,000 marine species across 34 phyla. Marine organisms 
comprise approximately half of the total biodiversity on earth and have shown to 
produce novel biomolecules (4, 5). In the past 50 years, exploration of marine 
bioresources for their unique natural products has been an important area of research. 
Of the estimated 270,000 known natural products, 30,000 compounds have been 
obtained from marine organisms (Blunt et al., 2015). Out of these, 9 are approved as 
medical drugs and 12 are undergoing clinical trials (Table 1.1) (6).    
Table 1.1: Marine natural products that are FDA-approved agents or used in clinical 
trial (6) 
Clinical 
Status 
Compound 
Name 
Source 
Organism 
Structural class Molecular 
Target 
Disease Area 
FDA 
approved 
Cytarabine (Ara-
C) 
Sponge Nucleoside DNA 
polymerase 
Cancer 
FDA 
approved 
Vidarabine (Ara-
A) 
Sponge Nucleoside Viral DNA 
polymerase I 
Antiviral 
FDA 
approved 
Ziconotide Cone Snail Cysteine Knot 
Peptide 
N-type 
Ca
2+
channel 
Pain 
 
FDA 
approved 
Eribulin 
Mesylate 
(E7389) 
Sponge Complex 
Polyketide 
Microtubules Cancer 
FDA 
approved 
Omega-3-acid 
ethyl esters 
Fish Omega-3 fatty 
acids 
Triglyceride-
synthesizing 
enzymes 
 
Hypertriglyceridemia 
Chapter 1 
3 
 
FDA 
approved 
Trabectedin (ET-
743) (EU 
registered only) 
Tunicate NRPS-derived 
Alkaloid 
Minor groove 
of DNA 
Cancer 
FDA 
approved 
Brentuximab 
vedotin (SGN-
35) 
Mollusk Antibody drug 
conjugate (MM 
auristatin E) – 
Linear 
NRPS/PKS 
CD30 and 
microtubules 
Cancer 
Phase III Plitidepsin 
(Aplidine) 
Tunicate Cyclic 
Depsipeptide 
Rac1 and JNK 
activation 
Cancer 
Phase II DMXBA (GTS-
21) 
Worm Alkaloid α7 nicotinic 
acetylcholine 
receptor 
Cognition, 
Schizophrenia 
Phase III Plinabulin (NPI 
2358) 
Fungus Diketopiperazine Microtubules 
and JNK stress 
protein 
Cancer 
Phase II Elisidepsin Mollusk Cyclic 
Depsipeptide 
Plasma 
membrane 
fluidity 
Cancer 
Phase II Zalypsis 
(PM00104) 
Nudibranch Alkaloid DNA binding Cancer 
Phase II Glembatumumab 
vedotin (CDX-
011) 
Mollusk Antibody drug 
conjugate (MM 
auristatin E) – 
Linear 
NRPS/PKS 
Glycoprotein 
NMB & 
microtubules 
Cancer 
Phase I Marizomib 
(Salinosporamide 
A; NPI-0052) 
Bacterium NRPS with β-
lactone & γ-
lactam 
20S 
proteasome 
Cancer 
Phase I Trabectedin 
analog 
(PM01183) 
Tunicate NRPS Alkaloid Minor groove 
of 
DNA<comma> 
Nucleotide 
Excision 
Repair 
Cancer 
Phase I SGN-75 Mollusk Antibody drug 
conjugate (MM 
auristatin F) – 
Linear 
NRPS/PKS 
CD70 and 
microtubules 
Cancer 
Phase I ASG-5ME Mollusk Antibody drug 
conjugate (MM 
auristatin E) - 
linear 
NRPS/PKS 
ASG-5 and 
microtubules 
Cancer 
Phase I Hemiasterlin 
derivative 
(E7974) 
Sponge Modified linear 
tripeptide 
(NRPS-PKS) 
Microtubules Cancer 
Phase I Bryostatin 1 Bryozoan Polyketide Protein kinase 
C 
Cancer, Alzheimer's 
 
Phase I Pseudopterosins Soft Coral Diterpene 
glycoside 
Eicosanoid 
metabolism 
Wound healing 
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An extreme physical and chemical condition in the marine environment create stress 
that contributes to the production of a unique variety of biomolecules by marine 
organisms (7). Sponges, corals and other marine invertebrates have been an ongoing 
source of novel chemical structures with many of these compounds exhibiting 
interesting biological activities. However, the applicability of many promising 
substances was hampered due to the presence of these organisms in relatively low 
amounts and the complex structures making chemical synthesis at scale difficult. 
Low recovery rates (less than 1 gm of substances such as halichondrin, ecteinascidin 
or bryostatin obtained from a ton of sponges, ascidia or bryozoa, respectively) as well 
as problems associated with mariculture of most marine macroorganisms made it 
extremely difficult to produce substances in amounts sufficient for further studies (8, 
9). Thus, marine microbial bioresources such as cyanobacteria, fungi and diverse 
groups of marine eubacteria were of interest since many of these organisms can be 
produced through fermentation at large scale. In fact, some compounds previously 
isolated from macro-organisms, such as sponges and tunicates, were actually 
metabolic products of associated microbes (10).  
 
Approximately 3000 natural products have been identified from marine micro-
organisms by the end of 2008 (11). Some marine bacteria and fungi have provided 
promising new lead structures for drug discovery (12, 13). An important example is 
the discovery of Cephalosporin C (a non-ribosomal peptide secondary metabolite) 
from the marine fungi Cephalosporium sp. (14). Over the past decade, more than 
10,000 marine natural products have been isolated from marine organisms including 
marine fungi (2, 7). During this period, approximately 1000 new natural products 
have been isolated from marine fungi, including terpenoids, alkaloids, shikimate-
derived metabolites, lipids and most importantly polyketides and non-ribosomal 
peptides (NRPs) (14). These compounds have a potential as pharmaceuticals, 
nutraceuticals and cosmeceuticals. 
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1.2. Natural products from marine fungi 
Terrestrial fungi have been more widely investigated for bioactive secondary 
compound production than marine fungi. Marine fungi are more difficult to collect 
and grow and sometime require high salt levels, causing fermentor corrosion.  These 
fungi are divided into two groups on the basis of their ability to grow in marine 
conditions, as obligate and facultative marine fungi (15). Obligate marine fungi grow 
fast and sporulate exclusively in a marine or estuarine habitat, while facultative 
marine fungi are generally obtained from fresh water or terrestrial environment that 
can grow (and possibly sporulate) in the marine environment (15). Marine fungi are 
mostly found in algae, corals and detritus of marine macrophytes. Over 1500 species 
of marine fungi including about 530 species of obligate marine fungi are known. At 
present, it is difficult to ascertain the obligate or facultative nature of fungi and 
therefore, a more general expression “marine-derived fungi” is used (16). Durieu and 
Montagne (1869) discovered the first obligate marine fungus on the rhizomes of the 
sea grass, Posidonia oceanica. The first facultative marine fungus, Phaeosphaeria 
typharum, was identified by Desmazieres in 1849 (15).  
Marine fungi are major decomposers of woody and herbaceous substrates in marine 
ecosystems and they also degrade dead animal (17). A broad variety of substrates are 
available in marine and estuarine environments for fungal growth. These include 
seaweeds, decaying leaves, mangroves, dead animals, algae and shells of various 
mollusks (14). Most of these fungi grow on lignocellulosic material in the coastal as 
well as deep sea environments (18). Coral reefs are also a rich source of marine fungi 
that produce novel secondary metabolites due to the presence of other biotic 
components present in the reefs (19). Till date, 3047 species of fungi have been 
reported from aquatic habitats around the world (Table 1.2). Worldwide, nearly 
100000 fungal species are known and about 27500 species are reported in India. The 
higher filamentous marine fungi include 530 species in 321 genera, which includes 
Ascomycota (424 sp. 251 genera), Mitosporic fungi (94 sp. 61 genera) and 
Basidiomycota (12 sp. 9 genera) (20, 21). 
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Table 1.2: Fungi from aquatic habitats from around the world Adapted from (22) 
 
Marine fungi may have developed specific metabolic pathways that are not seen in 
terrestrial fungi (23, 24). Marine mangroves and algicolous fungi are signiﬁcant 
sources of new bioactive compounds (16). The production of secondary metabolites 
seems highly dependent on the culture conditions and the origin of strains (25). The 
use of seawater for isolation and growth of marine-derived fungal species can 
enhance the recovery of fungi that yield secondary metabolites, as compared to the 
use of media prepared in distilled water (26-30). To produce these metabolites and to 
maximize the potential chemical diversity, they need to be grown in various nutrient 
limited media by varying carbon and nitrogen concentration. 
 
Fungi can be cultivated for the isolation of a number of metabolites such as 
glucoamlyase, amylase, α-glucosidase, and proteases. For example, Penicillium sp. 
grown under limited carbon has shown to produce penicillins, whereas same fungi 
grown under phosphorus and nitrogen limitation produce cephalosphorin, 
vancomycin, and carbapenems (31). It is impossible to estimate how many marine 
derived fungi have been screened so far for bioactive compounds. But the number of 
new bioactive compounds reported from marine fungi has increased steadily over the 
years: 1 (1981), 100 (2002), 272 (2004) with l690 new bioactive compounds reported 
from 2006 – 2010 (14,32,33). A broad array of pharmacological activities, ranging 
Taxonomic group Number of species 
Chytridiomycota 576 
Freshwater meiosporic ascomycota 450 
Mangrove meiosporic ascomycota 612 
Marine meiosporic and mitosporic ascomycota 465 
Indoldian meiosporic fungi 290 
Aeroaquatic meiosporic fungi 90 
Miscellaneous meiosporic fungi 405 
Oomycota (Saprolegniales) 138 
Basidiomycota from freshwater habitats  11 
Basidiomycota from brackish and marine habitats  10 
Total number  3047 
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from antimicrobial to anti-cancerous has been found in fungal metabolites (14), 
although only a few marine fungal derived drugs are currently in the market (34). 
 
1.2.1. Rate limiting factors for secondary metabolites biosynthesis in marine fungi 
 
Secondary metabolites are synthesized mainly under stress conditions due to either 
nutrition limitation or excess of carbon sources. The five main sources for the 
synthesis of secondary metabolites are (1) amino acids, (2) shikimic acid pathway, 
(3) polyketide biosynthesis pathway from acetyl-CoA, (4) mevalonic acid pathway 
from acetyl-CoA (5) polysaccharides and peptidopolysaccharides. The production of 
secondary metabolites by marine fungi varies due to several factors such as media 
composition, salt concentration and other fermentation processes. The effect of sea 
water concentration on hyphal growth and anti-microbial metabolite production was 
studied in various marine fungal strains and was found to increase the hyphal as well 
as metabolite production with increased sea water concentration (26, 27). 
 
The antibiotic lipoxazolidinones produced by the marine fungal strain NPS8920 and 
levels increase in natural sea water based media (29). Miao et al., (30), also estimated 
the effect of salinity and nutrition on the growth and bioactivity of marine fungi 
Arthrinium c.f. saccharicola. This study concluded that higher salt concentration 
decreased fungal growth but increased bioactivity. Also, the higher concentration of 
peptone and malt extract in growth media enhances fungal growth but decreases 
antibacterial activity, whereas the opposite occurred at higher glucose concentrations. 
Wang et al., (28), studied secondary metabolites production in the marine fungi, 
Spicaria elegans at 3% and 10% salinity. Five new compounds were produced at 
10% salinity, which was absent at 3% salinity. Thus it can be concluded that 
regulation of physicochemical conditions is important for optimizing secondary 
metabolite production in marine fungi.  
1.3. Marine cosmeceuticals  
 
The word cosmeceutical has been derived from blending of the terms „cosmetic‟ and 
„pharmaceuticals‟ by Abbert Kligman in 1984 (35). Cosmeceuticals are topical or 
oral cosmetic pharmaceutical hybrids intended to enhance beauty through bioactive 
ingredient having a drug like benefits (36, 37). Therefore cosmetics have been placed 
between non-prescribed and prescribed products (38). Cosmetics are defined as 
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substance intended to be applied to the human body for cleaning, beautifying, 
promoting attractiveness without affecting its structure and function (Figure 1.1). It 
is anticipated that the global cosmeceuticals market will reach US$ 61 Billion by 
2020. (http://www.researchandmarkets.com/research/246mph/global) 
 
 
        Figure 1.1: Cosmetics and their relative branches  
 
1.3.1. Current status of cosmetics-cosmeceuticals  
 
A variety of lifestyle and environmental factors cause various cosmetics and 
dermatological problems (37). Natural cosmeceutical products that are safe and 
efficacious are important for overcoming these problems. Plant derived ingredients 
have some limitations because plants can contain toxic metabolites, grow too slow or 
composition varies by seasonal changes (39). Marine flora and fauna produce 
chemically different biomolecules in comparison to terrestrial sources and so are of 
interest, particularly where organisms can be grown in large quantities, such as 
macro- and microalgae. Examples include the Greek company Apivita that is using 
sea fennel in sun care products, whilst Italy-based Lacote has a comprehensive range 
of anti-cellulite skin care products formulated with Guam seaweed. Sea algae, rich in 
vitamins and minerals, are becoming a common source of anti-ageing actives. Other 
brands are using sea minerals in their formulations, looking to emulate the success of 
Dead Sea mineral-based products.   
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The popularity of marine ingredients is leading to concerns that large-scale sourcing, 
or non-sustainable production methods, could disrupt marine ecosystems already 
under strain. Marine microorganisms can be grown outside of the ocean in fermenters 
and so are sustainable. Many novel bioactive molecules have been isolated from 
marine plants, animals and microbes for cosmeceutical applications, including 
phlorotannins, polysaccharides, carotenoid pigments, collagen, chitooligosaccharide 
(COS) derivatives, enzymes, peptides and other natural materials. For example, 
Phlorotanins from marine algae Ecklonia cava have anti-wrinkle (40) and anti 
tyrosinase activity (41). Some of these biomolecules are produced commercially by 
culturing specific marine organism which is used in cosmetics e.g. Myrothenones A 
and B (Cyclopentenone) from Myrothecium sp. (marine fungi) and Homothallin-II 
from Trichoderma viride H1-7 have skin whitening activity (42, 43). Moreover, 
various marine natural products including nutritional supplement ingredients are 
being developed into cosmeceutical (Table 1.3).  
Table 1.3: Examples of some cosmeceutical ingredients from marine sources Adapted 
and modified from (37) 
 
Cosmetic Ingredients Marine Resources Applications/Activities 
Mussel glycogen Sepia subaculeate Give smoothness brightness and luster 
to skin 
Aluminum silicate Sea mud Anticaking agent, Anti- psoriasis 
Shell powder Oysters Skin whitening, scrubs 
Turtle oil Chelonia mydas Smoothing and moisturizing agent 
Phycoerythrin pigments 
protein 
Red algae Pigment 
Proteoglycans Brown algae Boost skin collagen , improve skin 
density 
Omega-3-fatty acids Algae, animals Tissue repair, increase skin collagen 
production 
Peptide Sea weeds, sea food By- 
product 
Increase skin collagen production 
Phytoplankton Sea animals Cellular regeneration 
Collagen Marine fish Anti-wrinkle, sunscreen 
 
However, the potential of secondary metabolites from marine fungi as a 
cosmeceutical ingredient has only been partially evaluated. Only a few compounds 
have been isolated and utilized as a cosmetic ingredient from marine fungi. 
Therefore, there is considerable potential in screening marine fungal isolates and 
their secondary metabolites for their cosmeceutical efficacy. 
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1.4. Cosmeceuticals from marine fungi 
 
Skin is the largest organ in our body and it plays an extremely important role in 
protecting our body from external environmental stress and pathogens. Skin 
cosmeceuticals were developed after research on common skin problems like 
hyperpigmentation, skin cancer, skin microbial infections, wound healing, and 
wrinkles associated with sun damage and aging (Figure 1.2). 
 
Figure 1.2: Worldwide major skin problems and their probable solutions  
 
1.4.1. Marine fungi for prevention of skin aging and cancer 
 
According to Euromonitor International, anti-aging skin care is a large and dynamic 
business, covering 22% of the global skin care market, worth US$ 66 billion in 2007 
and is supposed to reach US$ 131 billion by 2019 (44, 45). The United States 
population of individuals over the age of 65 represented 13% in 2000 and it is 
expected to increase to 20% by 2030 (46). This data indicates an upcoming 
requirement for increasing efforts to prevent aging, including developing safe and 
effective cosmeceuticals. 
Aging is a complex, multifactorial biological process that occurs in all living 
creatures at variable rates. Various surgical and topical methods have been applied to 
alter the aging process (47). There are two types of skin aging processes, intrinsic 
and extrinsic. The intrinsic or innate aging refers to the natural programmed cellular 
aging. It is characterized by a decrease in collagen synthesis, degeneration of elastic 
fiber networks, and loss of hydration. On the other hand, extrinsic aging (premature 
cutaneous aging) occurs as the result of external factors such as smoking, excessive 
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alcohol consumption, poor nutrition, pollution, and particularly solar exposure. Solar 
exposure mostly causes skin wrinkling and undesired pigmentation. Extrinsic aging, 
also known as photo aging, has been studied extensively (48). Skin aging is governed 
by intrinsic genetic factors and mediated by extrinsic inﬂuences. Telomere shortening 
and metabolic oxidative damage generates reactive oxygen species (ROS), play a 
critical role in the aging process. Healthy telomeres are essential for a long life of 
cells but it shortens with aging. Telomerase (eukaryotic ribonucleoprotein (RNP) 
complex, contains an essential RNA and a protein reverse transcriptase subunit) is an 
enzyme which is responsible for maintaining the length of telomeres by an addition 
of guanine rich repetitive sequences (49). Thus, regulating telomerase activity delay 
the aging process.  
Current research has proven that telomeres and telomerase have a strong correlation 
to aging and cancer (50, 51). Telomerase (eukaryotic ribonucleoprotein, RNP) 
maintains telomere length stability in almost all cancer cells. Until now there has 
been no report on any topical skin care product, systemic drugs, or any other 
treatment options that can target telomerase for aging and cancer therapeutic 
approaches (inhibit telomerase with the intention of imparting anti-proliferative and 
apoptosis inducing effects (52). Only a few biomolecules have been isolated from 
various terrestrial as well as marine sources as telomerase inhibitors from marine 
sources. Example: Dictyodendrins A–E, five new alkaloids were isolated from the 
marine sponge Dictyodendrilla verongiformis, which inhibited telomerase 
completely at a concentration of 50µg/ml (53). Marine sponge Axinella infundibula 
were the source of Axinelloside A (highly sulfated lipopolysaccharide), Meridine and 
ascididemin. All of these compounds strongly inhibit human telomerase at IC50 
values of 2.0 µg/ml, 11 and ≥80µl respectively (54, 55) (Figure 1.3). Until now no 
such activities has been reported with marine fungal secondary metabolites. Hence 
exploring marine fungi for such targets may provide new molecules to treat these 
problems.  
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Figure 1.3: Telomerase inhibitors from marine sources  
 
1.4.2. Marine fungi for skin whitening  
 
Human skin color ranges from the darkest brown to the lightest pinkish-white due to 
the presence of melanin. Melanin is the major skin pigment that protects skin from 
harmful UV radiation. Longer exposure to ultraviolet (UV) radiation increases skin 
melanogenesis and usually results in darkening of the skin. However, it may also 
occasionally lead to the development of hyperpigmentation.  
The biosynthesis pathway for melanin formation was first elucidated by Raper in 
1928 and later modified by Cooksey in 1997. Tyrosinase (EC 1.14.18.1), a copper-
containing glycoprotein, is located in the membrane of melanosome and produced 
only by melanocytic (56). Melanogenesis takes place in the melanosomes by three 
specific enzymes namely, tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2. 
There are two types of melanin which are synthesized within melanosomes: 
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eumelanin (a dark brown-black insoluble polymer) and pheomelanin (light red-
yellow sulphur-containing polymer). L-tyrosine amino acid is the building stone 
which acts as a substrate for the enzyme and is generally transported into the 
melanosome by facilitated diffusion. The two proteins TRP-1 and TRP-2 are 
structurally related to tyrosinase and share approximately 40% amino acid homology. 
TRP-1 increases the ratio of eumelanin to pheomelanin and hence increases 
tyrosinase stability (57, 58). Tyrosinase, catalyzes the ﬁrst two steps of melanin 
synthesis, that is, hydroxylation of L-tyrosine to dopaquinone that is subsequently 
converted into L-dihydroxyphenylalanine (L-DOPA) through auto-oxidation 
followed by oxidation of DOPA is converted to dopaquinone (59, 60). The remaining 
steps of the melanogenic pathway are shown in Figure 1.4 which includes the 
synthesis of eumelanin and pheomelanin.  
Tyrosinase inhibitors have been proposed to be clinically useful for the treatment of 
some dermatological diseases associated with melanin synthesis like 
hyperpigmentation, melasma, cafe´aulait spot and solar lentigo, and are important in 
cosmetics applications such as skin lightening (61). A large number of in vitro 
tyrosinase inhibitors have been found, although only a few have shown to exhibit any 
significant effects in clinical trials (62, 63).  
 
 
Figure 1.4:  Synthesis of melanin (62) 
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Table 1.4 and Figure 1.5 describe in vitro tyrosinase inhibitors from marine fungi. 
Two new 3-amino-5-ethenylcyclopentenones, myrothenones A and B have been 
isolated from fungus of genus of Myrothecium. Only myrothenones A exhibited 
tyrosinase inhibitory activity, with an IC50 value of 0.8 muM. This compound is more 
active than kojic acid (IC50 value 7.7 muM)(43), which is currently used in various 
skin whitening products. The marine fungus Botrytis sp. was the source of a new α-
Pyrone derivative, 6-[(E)-Hept-1-enyl]-α-pyrone. This compound also exhibited 
greater tyrosinase inhibitory activity than kojic acid (IC50 value 4.5, 15.5 μM 
respectively)(64). A competitive inhibitor of mushroom tyrosinase homothallin-II 
have been isolated from marine derive T. viride (42). Two new sesquiterpenes, 1β, 
5α, 6α, 14-tetraacetoxy-9α-benzoyloxy-7β H-eudesman-2β, 11-diol and 4α, 5α-
diacetoxy-9α-benzoyloxy-7βH-eudesman-1β, 2β, 11, 14-tetraol, were produced as 
stress metabolites in the cultured mycelia of Pestalotiopsis sp. Z233 isolated from the 
algae Sargassum horneri. These compounds showed tyrosinase inhibitory activities 
with an IC50 value of 14.8 μM and 22.3 μM, respectively(65). 
 
Table 1.4: Tyrosinase inhibitors from marine fungi 
 
Sr. No. Source Biomolecule Cosmetic 
activity 
References 
1.  Myrothecium sp. 
(Marine fungi) 
Myrothenones A and B 
(Cyclopentenone) 
Tyrosinase 
Inhibitory 
(43) 
2.  Botrytis sp. 
(Marine fungi) 
6-[(E)-Hept-1-enyl]-α-pyrone 
(α-Pyrone Derivative) 
Tyrosinase 
Inhibitory 
(64) 
3.  T. viride H1-7 
(Marine fungi) 
Homothallin-II Tyrosinase 
Inhibitory 
(42) 
4.  Pestalotiopsis sp.    
Z233 (Fungi) 
 
 
1β,5α,6α,14-tetraacetoxy-9α-benzoyloxy-
7β H-eudesman-2β 11-diol and  
4α,5α-diacetoxy-9α-benzoyloxy-7βH-
eudesman-1β,2β,11, 14-tetraol 
Tyrosinase 
Inhibitory 
 
 
 
(65) 
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Figure 1.5: Structures of tyrosinase inhibitors from marine fungi 
 
1.4.3. Marine fungi for acne vulgaris 
 
Acne vulgaris (commonly known as acne or pimples) is the most common skin 
disorder caused by Propionibacterium acnes. It affects approximately 50 million 
people in US, and many more throughout the world. Globally more than 80% of the 
population suffers from acne at some stage in their life. Acne can be extremely 
painful and cause lasting marks or scars as well as lead to psychosocial suffering. 
Economically, it is estimated that US consumers spend more than 1.2 billion dollars 
each year for the treatment of acne (66). 
 
The prevalence of skin colonization by antibiotic-resistant P. acnes in acne patients 
over a 10-year period (67) showed that the proportion of patients with strains 
resistant to one or more commonly used anti-acne antibiotics is increasing. 
Therefore, there is a need to discover new biomolecules against P. acnes. Recently, 
Sargafuran obtained from marine brown algae, Sargassum macrocarpum has shown 
potent anti-acne activity (68). Two unusual pyridones, trichodin A and trichodin B, 
were extracted from mycelia and culture broth of the marine fungus, Trichoderma sp. 
strain MF106 isolated from the Greenland Seas (Figure 1.6). The trichodin A 
showed antibiotic activities against the clinically relevant microorganism, 
Staphylococcus epidermidis, with IC50 values of 24 μM and 4 μM, respectively (69). 
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Figure 1.6: Structure of Trichodin A-B 
2. Conclusion 
 
Marine research has and will continue to offer novel marine-based lead compounds 
for industrial applications. However, the immense microbial diversity of the marine 
environment is still only partially explored. Marine fungi are rich-sources of 
structurally diverse and pharmacologically active metabolites, with great industrial 
potential and accessibility, and thus they have attracted attention for health and 
cosmetic applications. The above literature presents research on marine fungal 
secondary metabolites and their application to skin aging, as well as for 
depigmentation and antimicrobial applications in the cosmetic industry. However, the 
use of fungal secondary metabolites for cosmeceutical application remains relatively 
unexplored, particularly for marine fungi. 
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3. Aim of this Research 
 
Natural products are important sources of drug and lead to drug discovery in a wide 
variety of therapeutic indications. The primary aim of this study was to investigate 
Indian west coast and Islands as a possible source for novel marine fungal strains that 
produce secondary metabolites with cosmeceutical potential. 
 
My research objectives to established suitable methods for isolating marine fungi 
from various marine samples by plating methods and different culture conditions, 
and to establish artificial marine liquid culture media for fungal fermentation. 
 
Objectives for this project also included (a) setting up an assay model for 
cosmeceutical activity screening, (b) identification of the taxonomy of isolated active 
fungal strains, (c) extraction of secondary metabolites from active fungal culture 
broth using bioassay guided isolation methods and (d) identification and structure 
elucidation of isolated active pure compounds. 
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Isolation and purification of marine fungi from a 
range of marine environment in India
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2.1. Introduction  
The marine ecosystem is one of the most extreme, complex and the largest aquatic 
system on earth, which makes it difficult to fully investigate, including accessing its 
biodiversity. It includes oceans, intertidal ecology, salt marsh, lagoons, estuaries, 
coral reefs, mangroves, deep sea and sea floor. Marine habitats are generally divided 
into two types, coastal and open ocean habitats. Most marine life is found in coastal 
habitats (70). According to the Primordial Soup Theory, “the origin of life occurred 
in a body of water, possibly a pond or ocean, by the combination of chemicals and 
some form of energy which gave the building blocks like amino acids”, that may 
have led to the evolution of the newer species (71). The marine ecosystem has a vast 
variety of organisms that are different in their physiology and adaptations. According 
to the Global Biodiversity Assessment by the United Nations Environment Program, 
oceans consist of 178,000 marine species in 34 phyla. It is estimated that 102 fungi, 
103 bacteria, and 107 viruses are likely to exist in one milliliter of seawater (72). 
Marine fungi are extensively distributed in marine environments, are found on a wide 
variety of substrata (73) and at varying depths (74). Most of these fungi grow on 
lignocellulosic material in the coastal as well as deep sea environment (18). Coral 
reefs, decaying seaweeds, sand grains and the east skins of marine invertebrates are 
also a rich source of marine fungi (75). However, each substratum supports a specific 
mycota, but some species may also be found on other substrata. Marine fungi are an 
ecological group of organism and are to be found in all oceans of the world. Some 
fungi are restricted to tropical or temperate waters while others are cosmopolitan in 
their distribution (Jones, 1988). New species are still being described, especially 
from new sea areas and substrata which not previously examined for example 
mangroves (14, 21, 76). 
In India, the west coast and the Andaman Islands are one of the most important 
marine environments for its biogeological characteristics and has been not well 
studied with respect to marine fungi. Marine fungi are an important class of marine 
organisms that are responsible for recycling of complex organic material (77, 78) and 
biodeterioration of materials in the sea (79, 80). In addition to this, they are a very 
promising bioresource for discovering natural products that may be of economic 
importance (14, 81). In this chapter, we present data on the diversity and occurrence 
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of culturable marine fungi on various substrata (sea grasses, wood and seaweed) 
collected at various locations in the west coast and the Andaman Islands. 
2.2. Materials and methods 
2.2.1. Chemicals used  
All analytical grade chemicals were purchased from Fischer Scientific (Mumbai, 
India) and used without further purification. Potato dextrose agar (PDA), Malt extract 
and Mycological peptone were procured from HiMedia (Mumbai, India) and were 
sterilized by autoclaving at 1200C for 15 mins before use. 
 
2.2.2. Study area 
The study area covered the Western Coastal Plains that lies between Western Ghats 
and the Arabian Sea. The plains begin at Gujarat in the north and end at Kerala in the 
south. It also includes the states of Maharashtra, Goa and Karnataka. The rivers that 
flow through this region are Narmada, Tapi, Zuari and Mandovi. This vast area has a 
variety of niches such as the Gulf of Kutch, Gulf of Khambhat and Salsette Island. 
The Gulf of Kutch is an inlet of the Arabian Sea along the west coast of India, in the 
state of Gujarat. The maximum depth of Gulf of Kutch is 401 feet (122 m). The first 
national marine park of India is also situated in it. There are 42 islands on the 
Jamnagar coast in the Marine National Park, most of them surrounded by reefs. The 
Andaman Islands form an archipelago in the Bay of Bengal between India, to the 
west, and Myanmar, to the north and east.  
Sample collection was done from different beaches of the north and south Goa, 
which have very limited tourist activities like Arambol, Querim and Agonda beaches, 
and also from the marine estuary Chapora River. Samples have been collected from 
low tidal areas having high biodiversity. From Dwarka, samples have been collected 
from a small pit of sea water near the sea which was rich in marine algae and 
sediment. Various marine samples were also collected from Havelock beach in the 
Andaman Islands of India (Figure 2.1). 
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Figure 2.1: Sites of sample collection in India (Goa, Gujarat and Andaman Islands) 
 
2.2.3. Collection of samples 
Sample collection was done after the rainy season during no moon days and low-tide 
periods in November to December, since in the rainy season very high amount of 
terrestrial water have been mixed with sea water causing contamination with 
terrestrial organisms. Materials from the deep intertidal zone (depth ~5-10 meters) 
were sampled. Marine algae, sea sediments/ estuary sediments, sea plants, mangrove 
plants (wood, leaves, and roots), dead animals and sea water were collected in sterile 
polypropylene bags and screw cap bottles, respectively. The collected samples were 
brought to the laboratory for isolation and purification of marine fungi.  
 Marine Algae: - Algae samples (Caulerpa sp., Halimeda sp., Padina sp., 
Sargassum sp. and unidentified alga) were collected from different sites that 
are associated with coral, mangrove and woods along with sea water. 
 Sea sediments: - Sediments were collected from the inner part of the sea (2-
3 km from beach shore) along with sea water, using a large spatula (12” 
length).  
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 Sea plants: - Sea plants were collected when they come up during low tide, 
in a plastic bottle along with sea water. 
 Mangrove plants: - Mangrove plant species (Avicenna marina and 
Rhizophora sp.) were collected and stored in a sterile zip bag.  
 Dead animals: - Dead Sea animals like sea mussels and sea shell were 
collected sedimentation sites.   
 Sea Water: - Stratified samples of marine water were collected in pre sterile 
screw cap plastic 5 L bottle from six different depths, which varied from 5 to 
200 centimetres in depth.  
 
2.2.4. Isolation of marine fungi 
The sediment samples were diluted at 10 and 100 fold with autoclaved aged seawater 
(Sea water collected from Indian Ocean was stored at room temperature for more 
than 5 years and this was provided by Dr. Sandeep Garg from Goa University, India) 
and sea water was used directly as inoculum. 100 µl of each sample was spread onto 
PDA media plates (39 gm potato dextrose agar in 1,000 ml of naturally aged 
seawater, pH 7.5 ± 0.2). The antibiotics, streptomycin and penicillin, at 100 and 50 
mg/L concentrations respectively, were added to each agar plate to inhibit the growth 
of bacteria. Algal samples were rinsed with sterile aged seawater several times until 
sea sand was removed and then plated on media plates. Likewise, plant material and 
dead animals were sterilized with 70 % ethanol for 10 seconds to kill the residual 
epiphytes and washed with sterile seawater to remove ethanol, and dried with sterile 
tissue paper. Subsequently, the samples were cut into pieces using a sterilized knife 
and pressed onto the media to inoculate endophytic fungi. Two replicate media plates 
were used for each sample. All plates were incubated at room temperature (28 ± 2 
°C) for 21 days. After 2 days of incubation, media plates were examined daily for the 
presence of developing fungal growth. Distinct fungal colonies on the media plates 
were then transferred to new media plates with artificial sea water (ASW) (82), 
instead of natural sea water, for further purification and maintenance (83).   
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2.2.5. Growth assessment of marine-derived fungal strains using different media 
conditions   
Radial growth experiments were performed to assess the growth and development of 
isolated marine fungi to investigate the importance of specific nutrients. The 
experiments were performed on the following media: 
 
1.  Media A (PDA in 100% sea water with pH 7.5 (High nutrient) 
2. Media B (Sea water media (SWM), 1.0% glucose, 0.5% peptone, 0.1% yeast 
extract and 1.7% agar, final pH of 7.5) (Low nutrient) 
The agar plates (90mm) were inoculated at a central insertion point and the colony 
diameters were measured after 2, 5, 7, 10, 15 and 20 days of cultivation in an 
incubator at 28±2°C. Radial growth of a fungal colony measured by Vernier caliper, 
when the growth was not round the average of length and width was taken into the 
account.  Each experiment was carried out in triplicate. 
2.3. Results and Discussion 
A total of 70 fungal isolates were isolated from marine samples collected from 
various locations on the west coast and Islands of India (Figure 2.2, Table 2.1). 
Coral reefs are considered an excellent source for the isolation of marine fungi and 
other organisms having bioactivity (75). 28 Fungal strains were isolated from 
Dwarka (22.2377N x 68.9673E, Gujarat) and 13 strains from Paldi (23.0121N x 
72.5589E, Gujarat). A total of twelve marine fungi were isolated from sediments 
collected from havelock beach Andaman Islands (11.7400N x 92.6586E). 17 fungal 
strains were isolated from marine samples collected from different beaches in Goa 
(28.38N x 72.12E) (Table 2.2, Figure 2.3). However, several of these fungal isolates 
did not show any growth on lab prepared artificial media.    
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Table 2.1: Samples collected from different parts of India (21.7679° N, 78.8718° E) 
 
Sr. 
No 
Name of 
the Place 
Coordinates of 
the Place 
Types of 
sample 
collected 
Total 
Number 
of sample 
collected 
Conditions/ Date  
Goa
§
, India     (28º38' N x 72°12' E) 
1. Cacra 
Beach, 
North Goa 
15° 26' 52" N x  
73° 50' 19" E 
Sea 
sediments, 
sea weeds, 
sea animals, 
sea water 
10 Two day previous to NMD* 
Time:- 2-4 PM Low tide (-0.06), 
13/11/2012 
2. Arambol 
Beach, 
North Goa 
15° 41' 14" N x  
73° 42' 11" E  
Sea 
sediments, 
sea weeds, 
sea animals, 
sea water 
10 One day previous to NMD 
Time:- 3-5 PM Low tide (-0.01), 
13/11/2012 
3. Querim 
Beach, 
North Goa 
15° 42' 57" N x 
 73° 41' 25" E  
Sea 
sediments, 
sea weeds, 
sea animals, 
sea water 
 
15 NMD Time:- 4-5 PM 
Low tide (-0.12), 14/11/2012 
4. Agonda 
Beach, 
South Goa 
15° 2' 41" N x 
 73° 59' 8" E  
Sea 
sediments, 
sea weeds, 
sea animals, 
sea water 
12 One day after NMD 
Time:- 3:30-5 PM  Low tide (-
0.11), 14/11/2012 
5. Chapora 
River, North 
Goa 
15° 36' 21" N x  
73° 44' 26" E  
Sediments, 
water. 
2 Two day after NMD 
Time:- 4:30-5:30 PM Low tide (-
0.11), 15/11/2012 
Gujarat, India (23º00' N x 72°00' E) 
6. Dwarkanath 
Temple, 
Dwarka  
22.23' 77"N x  
68.96' 73"E 
Sea 
sediments, 
algae, sea 
water 
10 One day previous to NMD 
Time:- 1-3 PM Low tide (-0.02), 
20/12/2012 
7. Paldi 23.01' 21"N x  
72.55' 89"E 
Sea 
sediments, 
algae, sea 
water 
5 One day previous to NMD 
Time:- 4-5 PM Low tide (-0.02), 
20/12/2012 
Andaman and Nicobar, India (11.7400N x 92.6586 E) 
8. Havelock 
island 
11.58N x  
93.00E 
Sea 
sediments, 
algae, sea 
water, wood. 
5 One day previous to NMD 
Time:- 3-5 PM , 29/12/2012 
 
Note: - * NMD: - No moon day 
            §:- These beaches are relatively less explored by tourists and less contaminated 
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Figure 2.2: Different locations where sampling was done and material collected 
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Table 2.2: Pure fungal isolates obtained from the samples collected from different 
habitats 
 
 
 
 
Sr. 
No. 
Place  Coordinates of the 
Place 
No of 
fungal 
isolates 
Culturable 
fungal 
isolates  
Culture 
conditions 
for isolation 
A. Dwarka (Gujarat) 22.2377N x 68.9673E 28 10  
PDA media 
in sea water, 
28ºC 
B. Paldi  (Gujarat) 23.0121N x 72.5589E 13 06 
C. Andaman & Nicobar 11.7400N x 92.6586E 12 11 
D. Goa 28.38N x 72.12E 17 08 
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Figure 2.3: Plates showing the diversity of culturable fungal isolates from different 
parts of India (D= Dwarka, P= Paldi, AN= Andaman & Nicobar, G=Goa) 
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2.3.2. Effect of nutrient concentration on fungal growth 
Mycelial growth of the isolated marine fungi in different nutrient concentrations 
(media A and media B) was investigated after incubation at 28°C and the results are 
summarized in Table 2.3 and 2.4. The nutrient concentration greatly affected the 
growth of fungi. The fungus grew two times faster in high-nutrient media (medium 
A) than in low-nutrient media (medium B). The density and appearance of mycelia 
was greater in media A, however, sporulation occurred earlier in media B (Figure 4). 
Of the 35 fungi isolates, 3 strains grew more abundantly in media B, while the 
growth of remaining strains was suppressed. These findings will be utilized in later 
work to optimize bioactive metabolite production in these fungi. 
 
Table 2.3: Fungal mycelial growth on medium A 
 
Fungal code  Days                                  Radial growth diameter (in mm) 
2nd 5th  7th 10th 15th 20th  
P2 12 35 65 FPG FPG - 
P3/2 GI 15 30 40 60 FPG 
P4 10 15 19 30 40 55 
P8 24 50 FPG FPG FPG - 
P9 GI 30 65 FPG FPG - 
P10 16 28 40 50 66 FPG 
       
D2 GI 12 20 29 35 43 
D3 00 GI 10 24 40 66 
D4 22 55 FPG FPG - - 
D5 GI GI 10 20 25 30 
D6 13 24 40 50 60 FPG 
D8 GI 18 29 40 50 FPG 
D15 GI 14 24 40 52 60 
D25 25 28 FPG FPG - - 
D28 00 22 50 65 FPG - 
D34 15 28 55 70 FPG - 
       
AN1 35 FPG FPG FPG FPG - 
AN2 00 10 19 25 30 39 
AN4 GI 20 35 45 52 70 
AN5 10 25 40 50 65 FPG 
AN6/1 20 28 40 46 53 FPG 
AN6/2 40 FPG FPG FPG FPG - 
AN7 GI 22 35 50 70 FPG 
AN9 15 22 30 40 56 FPG 
AN10 10 20 35 50 65 FPG 
AN11 30 60 FPG FPG FPG FPG 
AN12 30 FPG FPG FPG FPG FPG 
       
G2 00 GI 40 70 FPG FPG 
G3 25 FPG FPG FPG FPG FPG 
G4 10 16 29 35 52 FPG 
G7 16 40 70 FPG FPG FPG 
G8 50 7 FPG FPG FPG FPG 
G10 GI 25 45 60 FPG - 
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G14 GI 10 30 45 50 62 
G15 GI 10 35 45 49 56 
 
 
Table 2.4: Fungal mycelial growth on medium B 
Fungal code  Days                                     Radial growth diameter (in mm) 
2nd 5th  7th 10th 15th 20th  
P2 12 26 55 FPG FPG FPG 
P3/2 GI 13 25 35 55 FPG 
P4 9 13 20 28 33 39 
P8 14 40 FPG FPG FPG FPG 
P9 GI 15 65 FPG FPG FPG 
P10 7 20 35 55 65 FPG 
       
D2 GI 10 16 25 32 40 
D3 00 GI 30 45 55 FPG 
D4 16 35 FPG FPG FPG FPG 
D5 GI GI 9 20 25 30 
D6 12 25 40 60 67 FPG 
D8 GI 18 30 40 60 FPG 
D15 GI 10 2 25 40 49 
D25 15 40 FPG FPG FPG FPG 
D28 00 20 45 65 FPG FPG 
D34 12 22 40 50 57 FPG 
       
AN1 24 55 FPG FPG FPG FPG 
AN2 GI 9 15 20 28 34 
AN4 GI 25 35 55 63 70 
AN5 GI 25 36 50 70 FPG 
AN6/1 15 20 32 41 50 FPG 
AN6/2 33 60 FPG FPG FPG FPG 
AN7 GI 20 30 55 70 FPG 
AN9 13 22 28 45 50 FPG 
AN10 GI 10 30 50 60 FPG 
AN11 00 30 FPG FPG FPG FPG 
AN12 25 FPG FPG FPG FPG FPG 
       
G2 GI 13 42 50 62 FPG 
G3 20 FPG FPG FPG FPG FPG 
G4 10 15 19 25 29 35 
G7 10 25 70 FPG FPG FPG 
G8 258 60 FPG FPG FPG FPG 
G10 GI 18 20 30 68 FPG 
G14 GI 5 20 30 40 44 
Chapter 2 
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G15 GI 5 25 25 45 49 
 
Note: GI= Growth initiate, FPG= Full Plate Growth, D= Dwarka, P= Paldi, AN= Andaman & 
Nicobar, G=Goa 
 
 
 
 
 
 
Figure 2.4: Fungal growth differences with nutrient avability on solid culture medium
Chapter 2 
 
33 
 
2.4. Conclusion  
70 marine fungi were isolated from various samples collected from the west coast 
and Andaman Island of India. Of these, only 35 strains were culturable. Radial 
growth experiments on different solid media plate showing a clear difference in 
fungal mycelia growth and spore formation. Higher mycelial production was 
observed in nutrient rich media and earlier spore formation was observed in nutrient 
deficient media. 
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Screening for antimicrobial activity of marine fungi 
against bacteria causing skin and wound infections in 
humans 
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3.1. Introduction  
Millions of people worldwide are affected by infectious diseases caused by bacteria 
and fungi (84). Skin and skin structure infections (SSSI) represent a significant 
category of infectious disease. Acute bacterial skin and skin-structure infection 
(ABSSSI) are among the most prevalent in the world and the 28th most common 
infections diagnosis in hospitalized patients (85, 86). According to U.S. Food and 
Drug Administration (FDA), ABSSSI can be divided into two categories, 
uncomplicated and complicated. Uncomplicated includes simple abscesses, 
impetiginous lesions, furuncles, and cellulitis, mainly caused by Staphylococcus 
aureus and Streptococcus pyogenes. Many traumatic wound infections can also be 
considered uncomplicated when they are the result of common skin colonizers that 
have entered through a break in the skin‟s natural defenses. These infections are 
typically monomicrobial and caused by Gram positive organisms (87). Complicated 
SSSIs characteristically involve deeper soft tissue or require significant surgical 
intervention, such as infected ulcers, burns, and major abscesses or a significant 
underlying disease state that complicates the response to treatment (88). The 
complicated category includes infections either involving superficial infections or 
abscesses in an anatomical site, such as the rectal area, where the risk of anaerobic or 
Gram-negative pathogen involvement is higher and should be considered 
complicated infections (89) (Figure 3.1). Antibiotics are among the most commonly 
used drugs. Since the discovery of penicillin by Sir Alexander Fleming in 1928, 
antibiotics have protected billions of lives and played an important role in human 
history. Unexpectedly, many pathogens have developed resistant towards current 
antibiotics and this problem has become more and more serious (90). Additionally, 
the revitalization of almost vanished pathogens like Mycobacterium tuberculosis and 
the emergence of some new infectious diseases, such as cryptococcal meningitis, 
toxoplasmosis, H1N1, Ebola and severe acute respiratory syndrome (SARS) (90, 91). 
All these new problems necessitate the continuous search for novel and alternative 
antibiotics and antifungals.   
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Figure 3.1: Causative pathogens involves in complicated skin infections (92) 
 
Natural products have a wide range of structural diversity and a history of discovery 
as new and novel antibiotics and chemotherapeutic agents. Terrestrial bacteria and 
fungi have been wisely screened as sources of valuable bioactive metabolites with 
novel structures for antibiotic purposes (93-95). However, the rediscovery of high 
numbers of previously reported compounds has significantly diminished the study of 
the terrestrial microbial resource (95). Recently, less explored habitats and ecological 
niches such as the oceans and extreme conditions are being investigated. Recent 
reviews demonstrate that marine fungi have become promising sources of bioactive 
compounds (14, 96, 97). Due to unique physiochemical conditions in the marine 
environments, marine-derived fungi have produced a variety of novel bioactive 
compounds that have a potential for pharmaceutical and industrial uses (98, 99). 
However, limited numbers of novel marine fungi have been isolated from marine 
habitats as compared to their estimated high biodiversity (100). Research on marine 
fungi has been relatively neglected, although the fungi are extremely potent 
producers of secondary metabolites and bioactive substances. 
 
In the last decade, many novel bioactive natural products from marine fungi have 
been discovered that possess cytotoxic, anticancer, antiviral, antibacterial or 
antifungal activities (32, 97). Marine fungal produced a wide range of secondary 
metabolites belonging to the alkaloids, macrolides, terpenoids, peptide derivatives 
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and other structure classes (101). These marine fungal derived compounds have 
provided new drug candidates to fight the infectious diseases (81). Although the most 
famous instance was the discovery of cephalosporins (non-ribosomal peptide) with 
cephalosporin C from a marine strain of Acremonium chrysogenum in 1945 by G. 
Brotzu (102), there are also more recent promising examples which include, halovir 
and its naturally occurring analogs, which are potent inhibitors of Herpes simplex 
viruses 1 and 2 from the marine-derived fungus of the genus Scytalidium (103). The 
sponge-derived fungus Penicillium chrysogenum provides a new alkaloid 
sorbicillactone A, with strong activity against leukemia cells and low cytotoxicity 
(104). The marine fungus Pestalotia sp. was the source of the new chlorinated 
benzophenone compound pestalone, which showed potent antibiotic activity against 
Methicillin-resistant Staphylococcus aureus (MRSA, MIC=37 ng/mL) and 
vancomycin-resistant Enterococcus faecium (VREF, MIC=78 ng/mL), revealing its 
potential as a new antibiotic (105).  
 
The aim of this study was to evaluate collected marine fungal strains from west coast 
and Islands of India for their ability to prevent the growth of causative pathogens 
involves in complicated skin infections. All 35 fungal strains that were able to be 
grown in media were screened for antibacterial activity and then the most active 
isolates were subjected to microscopic analysis and molecular identification using 
molecular biological techniques. Scanning electron microscopy (SEM) was also used 
to study the possible effects of extracts on targeted bacterial cells. 
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3.2. Materials and methods 
3.2.1.. Chemicals used 
All analytical grade chemicals were purchased from Fischer Scientific (Mumbai, 
India) and were used without further purification. Nutrient agar (NA), Nutrient broth 
(NB), Brain heart infusion agar (BHIA), Brain heart infusion broth (BHIB) and 
Müller-Hinton agar were procured from HiMedia (Mumbai, India) and were 
sterilized by autoclaving at 1200C for 15min at 15psi before use. 
3.2.2. Test organisms 
3.2.2.1. Marine fungi 
35 fungal strains used in this work were isolated from various marine samples 
collected from west coast and Islands of India (Chapter 2, Table 2.2 and Figure 2.3 in 
Section 2.3.1) 
 
3.2.2.2. Bacterial strains 
The following microorganisms were used for antimicrobial screening: Escherichia 
coli (MTCC-443), Pseudomonas aeruginosa (MTCC-424), Staphylococcus aureus 
(MTCC-96), Staphylococcus epidermidis (MTCC-3615), Micrococcus luteus 
(MTCC-106), Bacillus subtilis (MTCC-121), Bacillus megaterium (MTCC 1684) 
and Propionibacterium acnes (MTCC-1951). These organisms were procured from 
Institute of Microbial Technology (IMTECH) Chandigarh, India.  
 
3.2.2.3. Bacterial inoculum 
A loopful of pure colonies of the all tested microorganisms, except P. acnes, was 
inoculated into 20 ml nutrient broth and incubated at 37°C for 4 h. P. acnes was 
inoculated into 20 ml of brain heart infusion media broth with 1% glucose for 72 h 
under anaerobic conditions. Anaerobic condition during media preparation was 
maintained as described by Singh et al., 2014 (106).  The turbidity of all actively 
growing bacterial suspension was adjusted to match the turbidity standard of 0.5 
McFarland standard [(1.5 x 108 colony-forming unit, CFU/ml), prepared by mixing 
0.5 ml of 1.75% (w/v) barium chloride dihydrate to 99.5 ml of 0.18 M (v/v)] 
sulphuric acid with continuous mixing. The bacterial suspension so prepared was 
used for testing their sensitivity to the samples under investigation (107). 
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3.2.3. Broth fermentation and extraction 
All fungal strains were cultured in 500 ml Erlenmeyer flasks containing 200 ml of 
potato dextrose broth (PDB, HiMedia) and malt extract broth (malt extract 17gm/L, 
mycological  peptone  3gm/L) in (ASW), separately at 28 ± 2°C for 15-20 days under 
shaking conditions at 140 rpm. After 20 days fermentation (Initially fungal growth 
curve study was performed using ergosterol assay to evaluation optimum growth in 
liquid broth), broths were separated from the mycelium by filtration. The supernatant 
was mixed with 10% activated Diaion HP-20 resin (Mitsubishi Chemical Co.) and 
the mixture was shaken for 30 min on a shaker. Then the mixture was packed in a 
glass column, washed with distilled water until the eluent was no longer cloudy and 
eluted with 50 ml methanol. Methanol was evaporated using a rotary evaporator 
(BUCHI Rota vapor R-200), and crude extract was collected and stored in the cold 
(108). The fungal mycelia were also soaked in methanol for 24 hours. The methanol 
layer was collected and evaporated to dryness to give the cell methanol extract. The 
broth and mycelial extracts were compared on TLC and when they were found same 
both the extracts were pooled (Figure 3.2). The dry crude extracts were dissolved in 
autoclaved Milli-Q water to prepare stock solutions of 5 mg/ml and kept for 
biological testing. 
 
Figure 3.2: Fungal secondary metabolites extraction 
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3.2.4. Antimicrobial assay in vitro 
An agar well-diffusion method described by (109) was used to determine the 
antimicrobial activity. Mueller Hinton agar no. 2 (HiMedia, India) was prepared and 
cooled to 40 - 45ºC and the bacterial inoculum (1.5×108 CFU/mL, 0.5 McFarland) 
prepared above was then added aseptically to the molten agar and poured into sterile 
petri dishes to give a solid plate. Wells (6 mm diameter) were made in each of these 
plates using sterile cork borer. The wells were filled with 50 µl of test compound (5 
mg/ml). The plates were first incubated at 4 ºC for 15 min and then at 37ºC for 18-24 
h under aerobic and anaerobic conditions, respectively. The antimicrobial spectrum 
of the extract was determined for the bacterial species in terms of zone sizes around 
each well. The diameters of zones of inhibition (ZOI) produced by the test were 
recorded and compared with those produced by positive control antibiotic, 
tetracycline (5 mg/mL, Sigma-Aldrich). For negative control, pure solvent 
(autoclaved Milli-Q water) were used instead of the extract. The experiment was 
performed two times in triplicates to minimize error and to check the reproducibility 
of results. The average values were recorded. 
The % antimicrobial activity was calculated by applying the expression: 
 
 
 
 
3.2.5. Determination of minimum inhibitory concentration (MIC) 
 
The MIC of active extracts were determined by a microdilution assay in 96-well 
microtiter plates according to the broth microdilution guideline of the Clinical and 
Laboratory Standards Institute (CLSI)(110). The fresh cultures were prepared at 24 h 
and 72 h broth cultures of E. coli, P. aeruginosa, S. aureus, S. epidermidis, M. luteus, 
B. subtilis, B. megaterium and P. acnes and OD was set at 0.5 McFarland standard 
(1.5×108 CFU/mL) at 600 nm with respective media broth. The bacterial suspension 
and the serially diluted (1, 0.5, 0.25, 0.07 mg/mL) fungal crude extracts were added 
to 96-well plates to obtain the final volume of 200 µl. The microplates were 
incubated at 37˚C with continuous shaking. After 18 h and 48 h (for P. acne), the 
optical density at 600 nm was measured with a microplate reader. Tetracycline was 
% Inhibition= 100 - (ZOI positive control − ZOI sample) / ZOI positive control ×100  
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used as positive controls. The MIC values were determined at the zero optical density 
concentration. All experiments were repeated three times. 
3.2.6. Determination of the antibacterial mechanism 
 
Extracts with strong antimicrobial activity were further investigated for their possible 
effects on targeted cells by scanning electron microscopic analysis. All test 
organisms were grown overnight to mid-logarithmic phase or at a fixed OD of 1.5 at 
600 nm. All test organisms in the present study were treated with a fixed 
concentration of 2 mg/mL of crude fungal extracts and incubated at 37˚C with 
continuous shaking. After 18 h and 48 h (for P. acne) the culture was centrifuged at 
5,000 rpm for 5 min; the supernatant was removed and washed three times with 
startle water. Test organisms were then fixed in 2.5% glutraldehyde in 25mm 
phosphate buffer solution (PBS) for 5-6 hrs at 4°C, then washed with PBS 3 times for 
10 min. Then the sample was dehydrated with an ethanol series (30%, 50%, 70%, 
90% and 100% ethanol). Samples were dried using a critical point dryer (Emitech 
K850, Berkshire, U.K.) were sputtered coated with gold and palladium coating at 
120mA for 15 mins using sputter coater (Quorum Technologies SC7620, Berkshire, 
U.K). The samples were scanned under SEM (Model EVMA10, ZEISS, Germany) at 
TERI-Deakin Nano Biotechnology Centre. 
 
3.2.7. Morphological and molecular characterization of potential marine fungi strain  
The bioactive fungal isolates were identified initially by morphological 
characterization by scanning electron microscopy (SEM, Model EVMA10, ZEISS, 
Germany). Subsequently, they were identified by molecular techniques based on the 
analyses of their nuclear ribosomal internal transcribed spacer (ITS) regions.   
3.2.7.1. Scanning electron microscopy (SEM) of fungi  
Morphological features of selective fungal isolates were observed through SEM (Carl 
Zeiss, Oberkochen, Germany). Fungal isolates were cultured on PDA sea water 
media and incubated at 280C ± 2 for 4-5 days. After that, fungal growth was taken 
and then immersed in a fixative solution (Modified Karnovsky‟s fixative 2.5% 
glutaraldehyde- 2.5% paraformaldehyde, 0.05M cacodilate buffer, 0.001M CaCl2) at 
pH 7.2, followed by washing with Cacodilate buffer (thrice for 10mins each). Then 
post-fixation was done by 1% osmium tetraoxide solution and water for 1hr (111). 
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The samples were then washed with sterile distilled water three times and then 
subjected to dehydration in acetone (25%, 50%, 75%, 90% and 100%) for 10 min 
each followed by critical point drying (CPD) (Emitech K850, Berkshire, U.K.). The 
samples were assembled on double-sided carbon tape placed on aluminum stubs. The 
samples were then coated with gold-palladium in a sputter coater (Quorum 
Technologies SC7620, Berkshire, U.K.) and viewed in SEM at an accelerating 
voltage of 10kV.  
3.2.7.2. DNA extraction, PCR amplification and sequencing   
Fungi were cultured in potato dextrose broth (PDB) in ASW for one week. Fungal 
genomic DNA was performed using the DNeasy Plant Mini Kit (Qiagen) following 
manufacturer‟s instruction. Primer pairs ITS1/ITS4 (5‟-TCC GTA GGT GAA CCT 
GCG G-3‟/ 5‟-TCC TCC GCT TAT TGA TAT GC-3‟) and 
ITS1F/ITS4B(5‟CTTGGTCATTTAGAGGAAGTAA3‟/5‟CAGGAGACTTGTACA
CGGTCCAG-3‟) were used for the PCR reactions (112). The final PCR reaction mix 
was of 25 µl reaction volumes containing 2.5 µl of 10x buffer, 1.5 µl of MgCl2 (25 
mM), 0.5 µl of dNTP (10 mM), 1 µl of ITS1 primer (5 pm), 1 µl of ITS4 primer (5 
pm), 0.2 µl of Taq Polymerase (2.5 U), 3 µl of DNA sample (5 µg/ ml), and 
remaining volume was made up using sterile Milli-Q Water. The PCR reaction was 
carried out in Veriti 96-well Thermal Cycler (Applied Biosystems, Massachusetts, 
U.S.A) with conditions as follows: denaturation for 5 min at 94ᵒC, 33 elongation 
cycles (50 s at 95˚C, 50 s at 56˚C, 1 min at 72ᵒC) final extension for 10 min at 72˚C 
and last at 4˚C. Negative controls were used to confirm the absence of contamination. 
The final products were analyzed by electrophoresis on 1% Agarose (Sigma-Aldrich, 
St. Louis, USA). The amplified DNA was cut from the gel using Gel extraction kit 
(Qiagen, Germany). The purified PCR-DNA products were sequenced by Xcelrislabs 
Ltd., an Indian Biotechnology Company using the same primers. The sequences were 
analyzed by Finch TV 1.4.0 (113). The sequences were then compared with the 
NCBI GenBank database by the BLASTN program. Phylogenetic relationships were 
estimated using MEGA7.0.18 (114).  
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3.3. Results and discussion: 
3.3.1. Antimicrobial screening 
Organic extracts of fermentation broth and mycelia of the 35 isolated marine fungi 
strains were screened for antibacterial activities at 5 mg/mL concentration against 
eight human pathogenic bacteria (E. coli, P. aeruginosa, S. aureus, S. epidermidis, 
M. luteus, B. subtilis, B. megaterium and P. acnes). As showed in Table 3.1, 18 
fungal strains (41.8 %) displayed different levels of antibacterial activities against the 
tested pathogenic bacteria. Among those, the malt extracts of fungal strains Dwarka 
5, Andaman 12, Goa 10 showed the strongest inhibition (93%, 86% and 83%, 
respectively) activity S. aureus.  PDA extract of Goa 10 and malt extracts of 
Andaman 12 and Goa 3 showed the strongest inhibitory activity against M. luteus, 
with 77%, 86%, 75%, respectively. Similarly, the growth of B. subtilis was strongly 
inhibited by malt extracts of Dwarka 5 and Andaman 10 and PDA extract of 
Andaman 10. PDB extracts of fungal strains Andaman 10 and Andaman 11 showed 
79%, 66% inhibition activity, respectively, against B. megaterium. The extract of 
Dwarka 5 showed higher inhibitory activity then did the positive control. The Growth 
of anaerobic bacteria P. acnes was strongly inhibited by PDA extracts of Dwarka 5 
and Goa 10 and malt extract of Andaman 12 (60%, 60% and 70%, respectively). 
PDA extracts of Dwarka 5 and Andaman 7 and malt extract of Andaman 10 all 
showed higher inhibition then the positive control against S. epidermidis. Growth of 
gram negative bacteria P. aeruginosa was effectively inhibited by PDA extracts of 
Dwarka 5 and Dwarka 6 (87%, 50%, respectively). Only PDA extract of Andaman 
10 showed inhibition against E. coli. 
 
In the present study, we found that crude extracts of some fungi had significant 
antibacterial activities. This indicates that different fungi can produce intracellular 
bioactive metabolites or secrete extracellular bioactive compounds. In addition, the 
results indicated that the fungal extracts exhibited higher inhibition activities to 
Gram-positive bacteria, such as P. acnes, S. aureus, B. subtilis and B. megaterium 
than to Gram-negative bacteria, which might be a result of different cell wall 
compositions of Gram-positive and Gram-negative bacteria. Many diseases are 
known to be caused by gram-positive bacteria, such as infections of the respiratory 
tract and skin. The gram- positive bacteria can produce exotoxin which can infect 
humans. The fungi with higher bioactivity toward gram-positive bacteria are a 
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possible source of new drug leads for development to eventually treat these diseases. 
Our results indicate that the marine-derived fungi isolated in this study are a 
promising source of natural product candidates for isolation and structural studies. 
Dwarka 5, Andaman 7, 10 and 12 were particularly promising and exhibited a broad 
range of activity. Subsequent experiments were conducted to determine minimum 
inhibitory concentrations and mode of action of selected fungal extracts.  
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Table 3.1: Antibacterial activity of crude fungal extracts against pathogens involves in 
complicated skin infections by agar well-diffusion method 
 
 
Zone of inhibition  
No
. 
Marin
e 
Fungi 
Code 
Media 
Extract 
 
Gram (+) bacteria Gram (-) 
bacteria 
S. 
aureu
s 
M. 
luteu
s 
B. 
subtili
s 
B. 
megaterium 
P. 
acnes 
S. 
epidermidi
s 
E. 
col
i 
P. 
aeruginos
a 
Diameter ( in mm)  Inclusive of 6 mm of well 
1.  P 2 PDA  - - 12  12  - - - - 
MALT - - - - - - - - 
2.  P 3/2 PDA  - - - - - - - - 
MALT - - - - - - - - 
3.  P 4 PDA  15  - - - - 16  - - 
MALT - - - - - - - - 
4.  P 8 PDA  11 20 - -  15 - - 
MALT - - - - - - - - 
5.  P 9 PDA  - - - - - - - - 
MALT - 10  - -  - - - 
6.  P 10 PDA  - - - - - - - - 
MALT - - - - - - - - 
7.  D 2 PDA  - - - - - - - - 
MALT - - - - - - - - 
8.  D 3 PDA  - - - - - - - - 
MALT - - - - - - - - 
9.  D 4  
 
PDA  - - - - - - - - 
MALT - - - - - - - - 
10.  D 5 
 
PDA  25  20 22 25  30  27  - 35  
MALT 28  22 23 25  30  12 Hz - 35  
11.  D 6  
 
PDA  15  17  13  12  15  11 Hz - 20  
MALT 16  17  12  12  17  16  - 20  
12.  D 8 
 
PDA  - - - - - - - - 
MALT - - - - 16  - - - 
13.  D 15 
 
PDA  11 - - - 10  - - - 
MALT - - - - - - - - 
14.  D 25 PDA  - - - - - - - - 
MALT - - - - - - - - 
15.  D 28 PDA  - - - - - - - - 
MALT - - - - - - - - 
16.  D 34 PDA  - - - - - - - - 
MALT - - - - - - - - 
17.  G 2 PDA  - - - - - - - - 
MALT - - - - - - - - 
18.  G 3 PDA  - - - - - - - - 
MALT 23  34  11  12  30  - - 15  
19.  G 4 
 
PDA  16  16  15 15 10  15 Hz -      15 Hz 
MALT 
 
- - - - - - -  -  
 
20.  G 7 
 
PDA  - - - - - - - - 
MALT - - - - - - - - 
21.  G 8 PDA  - 20  15  - 18  16  - - 
 
MALT - 16  14  - 16   - - 
22.  G 10 PDA  21  35 - - 30  - - 15  
MALT 25  32  - - 30 - - 12  
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Note: Hz = Hazy, D= Dwarka, P= Paldi, AN= Andaman & Nicobar, G=Goa 
 
 
3.3.2. Determination of minimum inhibitory concentration (MIC) 
The MIC of all active crude extracts was determined using a colorimetric micro 
dilution method. We have found that all active crude extract have shown 90-99 % 
inhibition at 1 mg/ml concentration against their respective bacterial strains (Figure 
3.3 A, B). We can conclude that the MIC values of the best active crude extracts 
ranged from 1 to 1.5 mg/ml. However this is the MIC value of crude extract and after 
getting bioactive compound one can decide the dose. It will also be decided after 
checking the toxicity dose of active principle. Further purification and identification 
of active compounds are described later in this thesis.  
23.  G 14 PDA  - - - - - - - - 
MALT - - - - - - - - 
24.  G 15 PDA  - - - - 10  - - - 
MALT - - - - - - - - 
25.  AN1 PDA  - - - - - - - - 
MALT 7  - - - - - - - 
26.  AN2 PDA  - - - - - - - - 
MALT - - - - 15  - - - 
27.  AN4 PDA  - - - - - - - - 
MALT - - - - - - - - 
28.  AN5 PDA  - - - - - - - - 
MALT - - - - - - - - 
29.  AN6/
1 
PDA  - - - - - - - - 
MALT - - - - - - - - 
30.  AN6/
2 
PDA  - - - - - - - - 
MALT - - - - - - - - 
31.  AN7  PDA  - 11  7  - 20  22  - 16 
MALT - - - - - - - - 
32.  AN9 PDA  - - - - - - - - 
MALT - - - - - - - - 
33.  AN10 PDA  17  17 
Hz 
20  19  10  16  15 16  
MALT 20  20 22  20  25  20  - 17  
34.  AN11  PDA  10  20  16  16  17  16  - - 
MALT - 11  7  - - - - - 
35.  AN12 PDA  15  19  - - - - - - 
MALT 26  39  14 14  35  - - 15  
36.  Tetra  WATER 30  45  25 24  50  16  35  40  
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Figure 3.3 A, B: MIC of active fungal crude extracts against respective bacteria 
 
3.3.3. Mechanism of action (SEM analysis) 
The effects of the most active crude extracts against their susceptible test 
microorganisms were investigated by SEM. SEM images of the targeted 8 bacterial 
cells revealed ultrastructural changes due to the active extracts. Control bacterial 
cells had well defined, intact shapes and were smooth. After treatment with crude 
extract (2mg/mL) for 18 hr. the cells showed considerable morphological alterations, 
including deformation, shrinkage, collapsed and broken cells. Cell wall shrinkage 
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and breakage were observed in S. aureus treated with D5, AN12 and G10 fungal 
extracts (Figure 3.4). Cell wall shrinkage and breakage were also observed in S. 
epidermidis treated with D5, AN7 and AN10 (Figure 3.5). Membrane invagination 
was observed in B. megaterium when treated with D5, AN10 and AN11 (Figure 3.6). 
Similarly, cell surface deformation was noticed in the cell surface of P. aeruginosa 
and E.coli cells treated with D5, D6 and AN10 (Figure 3.7). Cell wall shrinkage and 
breakage were observed in P. acnes treated with D5, AN12 and G10 fungal extracts 
(Figure 3.8). 
 
 
Figure 3.4: Effect of fungal crude extract on Staphylococcus aureus 
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Figure 3.5: Effect of fungal crude extract on Staphylococcus epidermidis 
 
 
 
 
Figure 3.6: Effect of fungal crude extract on Bacillus megaterium   
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Figure 3.7: Effect of fungal crude extract on Pseudomonas aeruginosa and E. coli 
 
 
 
 
Figure 3.8: Effect of fungal crude extract on Propionibacterium acnes 
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3.3.4. Identification of marine fungi with strong antibacterial activity 
 
A total of 35 isolates were screened for antibacterial activity. Consequently, eight 
strongly active marine fungal isolates (D5, D6, AN 7, AN 10, AN 11, AN 12, G 3, 
and G10) were selected for SEM, sequencing and identification based on ITS 
sequences (Figure 3.9, 3.10). According to NCBI nucleotide blast analysis, among 
the 8 identified fungi, all belonged to the phylum Ascomycota including genera 
Penicillium, Aspergillus, Emericellopsis, Simplicillium and Leptosphaerulina. These 
identified fungi and their best matches in the NCBI database are summarized in 
Table 3.2. Six isolates matched their closest relatives with 99 % similarity except for 
AN 7 (95%). It should be noted that the strain AN 7 was unsuccessfully identified on 
fungal ITS sequences.  
 
Table 3.2: Phylogenetic affiliations of selected fungi with strong antibacterial activity 
 
Strain Morphological 
identification 
Closest identified relative Access. No. Identity 
(% ) 
D 5 Simplicillium sp. Simplicillium lamellicola KC894712.1 99 
D 6 Emericellopsis sp Emericellopsis minima KT290876.1 99 
AN 7 Leptosphaerulina sp. Leptosphaerulina sp. JN850998.1 95 
AN 10 Penicillium sp. Penicillium citrinum KT898717.1 99 
AN 11 Aspergillus sp. Aspergillus aculeatus JX501355.1 99 
AN 12 Penicillium sp. Penicillium chrysogenum KU925907.1 99 
G 3 Aspergillus sp. Aspergillus oryzae HM145964.1 99 
G 10 Aspergillus sp. Aspergillus sydowii JN851052.1 100 
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Figure 3.9: SEM morphological analysis of most active sporulating fungi 
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Figure 3.10: Phylogenetic tree of partial ITS-rDNA sequences of marine fungal strains  
The evolutionary history was inferred us ing the Neighbor-Joining method. The optimal tree with the 
sum of branch length = 1.39517377 is  shown. The percentage of replicate trees in which the associated 
taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The tree is 
drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to  
infer the phylogenetic tree. The evolutionary distances were computed us ing the Maximum Composite 
Likelihood method and are in the units of the number of base substitutions per site. The analysis 
involved 43 nucleotide sequences. All positions containing gaps and missing data were eliminated. 
There were a total of 362 positions in the final dataset. Evolutionary analyses were conducted in 
MEGA7. 
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3.4. Discussion 
Thirty five fungal strains were selected which were isolated from range of marine 
environment in India. 8 isolates exhibited biological activity, representing 5 genera of 
fungi. Fungus “D5” was grouped with S. lamellicola (Figure 3.10), which is known 
to produce antibacterial mannosyl lipids, halymecins F and G and (3R,5R)-3-O-b-
Dmannosyl-3,5-dihydrodecanoic acid (115). In a recent study by (116), a S. 
lamellicola isolated from Antarctica marine sediments exhibited both antibacterial 
and antifungal activity.  
 
Fungus “D6” was grouped with E. minima (Figure 3.10) which is known to produce 
the sesquiterpenes (5E)-2-methyl-5-[(1'R*, 5'R*)-2-methylidene-7-oxobicyclo [3.2.1] 
oct-6-ylidene]-4-oxopentanoic acid and dihydroisocoumarin cis-(3R, 4R)-4-
hydroxymellein. Both compounds were found to show neither antimicrobial nor in 
vitro growth inhibitory activities on three human tumor cell lines (117). However, in 
our study, we found that the crude extract of our marine fungal strain D6 E. minima 
showed significant antibacterial activity. This could be because of the different hosts 
or culture conditions resulting in different production of secondary metabolites.  
Fungus “AN7” related to Leptosphaerulina sp. (Figure 3.10) was however not tested 
for any of these activities.  Recently (118), discovered new 6-methylpyridinone 
derivatives from the marine-derived fungus Leptosphaerulina sp. using 1H NMR 
prescreening and tracing the diagnostic signals. 
 
Out of 8 selected fungi only 2, “AN 10” and “AN 12”, were related to Penicillium sp. 
P. citrinum and P. chrysogenum (Figure 3.10). Both fungal strains displayed 
antimicrobial activity against both gram positive and negative bacteria.  In a study by 
(119), two structurally unique steroids, isocyclocitrinol A and 22-
acetylisocyclocitrinol A, were isolated from a saltwater culture of P. citrinum 
(Axinella sp., Papua New Guinea). Both compounds exhibited weak antibacterial 
activity against S. epidermidis and Enterococcus durans. Two new diterpene, JBIR–
59 and 124, were obtained from P. citrinum SpI080624G1f01 (Ishigaki Island, 
Okinawa,Japan) (120, 121). Two anthraquinone-citrinin derivatives penicillanthranin 
A  and B, isolated from P. citrinum PSU–F51 (Gorgonian, Annella sp., Similan 
Islands, Thailand) were found active against both the wild and methicillin-resistant S. 
aureus with a MIC value of 16 μg/ml (122). Penicitrinols G and H and 1,7-
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dihydroxy-8-(methoxycarbonyl)-9-oxo-9H-xanthene-3-carboxylic acid three 
polyketides were isolated from P. citrinum SCSGAF 0167 (Echinogorgia aurantiaca, 
South China Sea, China)(123). P. citrinum (Gastrointestine of the parrot fish Scalus 
ovifrons, Okinawa Island, Japan) produced scalusamides A–C in which only 
scalusamide A displayed antibacterial activity against M. luteus with a MIC value of 
33.3 μg/ml (124). 
 
Similarly chrysotriazoles A and B were obtained from endophytic P. chrysogenum 
(brown alga Sargassum palladium, Fujian, China)(125). The diketopiperazine 365 
was obtained from endophytic P. chrysogenum (mangrove leaves Porteresia 
coarctata, Chorao Is., Goa, India) and displayed antibacterial activity comparable to 
that of streptomycin (126). Recently (127), found that a crude extract of P. 
chrysogenum DSOA associated with Indian Ocean marine sponge (Tedania 
anhelans) exhibited antimycobacterial activity.  
 
Aspergillus species are mostly known for their role as a pathogen. However, they 
also play important roles in industry and our environment. Our last three fungi 
belong to same group. Fungus “AN 11” was grouped with A. aculeatus (Figure 
3.10), which is known to produce useful multi polysaccharide degrading enzymes for 
industrial applications (128). We did not assess enzymatic properties in our study. 
Several bioactive compounds have been isolated from the marine strain A. aculeatus 
in the last 10 years; however these strains have not been tested for any of these 
activities.  Fungus “G 3” was grouped with A. oryzae (Figure 3.10) which is known 
to produce the indoloditerpene derivatives Asporyzins A–C. Only asporyzin C 
exhibited strong activity against E. coli (129). Asporyergosterol was isolated from an 
endophytic A. oryzae (H. japonica, Yantai, China)(130). 
 
Fungus “G 10” was grouped with A. sydowii (Figure 3.10) which is known to 
produce M. tuberculosis protein tyrosine phosphatase A (PTPA) inhibitors sydowiol 
A–C (131). The endophytic fungus A. sydowii, isolated from the red alga 
Acanthophora spicifera (collected from Rameswaram, south India), produced two 
new chlorinated 2,5-diarylcyclopentenones, sydowins A and B (132). 
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3.5. Conclusion  
In this study, 35 marine fungi were screened for antibacterial activity. Eight fungi 
were successfully classified at the genus level based on ITS region sequences with 
relatives in the NCBI database, except for one isolate (AN 7). They were distributed 
among five genera (Penicillium, Aspergillus, Emericellopsis, Simplicillium and 
Leptosphaerulina). Crude extracts of these eight fungi displayed different levels of 
antibacterial activities to pathogenic bacteria, and some strains of the genera 
Penicillium, Emericellopsis and Simplicillium showed strong growth inhibition to S. 
aureus, S. epidermidis and M. luteus and P. acne. The combined data gathered from 
this investigation contributes to the knowledge of fungal diversity and antibacterial 
bioactivities associated with Indian marine environments. In conclusion, “D5” S. 
lamellicola was found to be the most potent fungi isolated in this study and is 
investigated in more detail, as described later in this thesis. 
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Chapter 4 
Screening of marine fungi for potential tyrosinase 
inhibitor and antioxidants 
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4.1. Introduction 
The skin is an essential organ of the body. It protects our body from adverse effects 
caused by direct contact with the outside environment. Ultraviolet (UV) irradiation is 
the most common and pernicious environmental factor that injures the skin (133). 
Melanin is a mixture of heterogeneous biopolymers, responsible for the color of 
human skin, hair, and eyes and protecting skin against radiation. The process of 
melanin synthesis is called melanogenesis; which occurs within melanosomes, 
membrane-bound granules, from melanocyte and is then transferred to keratinocytes 
(134). But the accumulation of abnormal melanin induces pigmentation disorders, 
such as melasma, freckles, ephelide, and senile lentigines (135). This process is 
regulated by a variety of environmental, hormonal, and genetic factors, such as 
ultraviolet (UV) exposure, α-melanocyte-stimulating hormone (α-MSH), 
melanocortin 1 receptor (MC1R), and agouti-related protein (136-138). Tyrosinase, a 
copper-containing monooxygenase, is a key enzyme that catalyzes melanin synthesis 
in melanocytes (139). Therefore, tyrosinase inhibitors may be clinically useful for the 
treatment of some dermatological diseases associated with melanin 
hyperpigmentation and important in cosmetics for skin whitening (140).  
 
In last decade, a large number of natural and synthetic compounds have been 
discovered or developed as tyrosinase inhibitors (62, 141). Many of them like kojic 
acid (142), arbutin, ascorbic acid derivatives, retinoic acid, azealic acid, ellagic acid, 
chlorophorin, norartocarpanone, hydroquinone, catechins, aloesin, resveratrol. 
oxyresveratrol, and 4,4′-dihydroxybiphenyl and other natural products are now in the 
market (63, 140). However, there are still serious health concerns with some of these 
ingredients, such as irreversible cutaneous damage, ochronosis, inflammation of 
synthetic compounds and less effectiveness of available natural products due to their 
adverse effects, poor skin penetrations, and low formulation stabilities (143, 144). 
More research is needed toward the discovery and development of new cosmetic 
ingredients, such as effective and safe tyrosinase inhibitors. 
An imbalance state between intracellular antioxidants and intracellular reactive 
oxygen species (ROS) or the so-called state of oxidative stress is a known 
contributing factor for a wide range of human diseases. For example, cancers, 
neurological disorders (Alzheimer and Parkinson), aging, atherosclerosis, diabetes, 
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rheumatoid arthritis, inflammation, and other oxygen related diseases (145, 146). 
Antioxidants are vital substances, playing an important role in the prevention of 
oxidative damage of biomolecules and cells and ROS-induced diseases by reacting 
with free radicals, scavenging free radicals and chelating free catalytic metals (147). 
Due to increasing safety concerns involved with consumption of synthetic 
antioxidants, exploitation of cheaper and safer sources of antioxidants from natural 
origins, and especially from marine sources, is of interest. The strong antioxidant 
power of some marine fungal species was demonstrated in several reviews (2, 148, 
149). Marine resources have are good sources of bioactive compounds for the 
development of new drugs and health foods. Marine fungi are known to be rich 
producer of a variety of natural products. Hence, there is the possibility to identify 
novel bioactive compounds with antityrosinase and antioxidant potential from marine 
fungi obtained from west coast and Islands of India. In this study, we investigated 
skin depigmenting and antioxidant activity of extracts from some recently collected 
marine fungal.  
4.2. Materials and methods 
4.2.1. Chemicals used 
All analytical grade chemicals were purchased from Fischer Scientific (Mumbai, 
India) and used as such without further purification. Mushroom tyrosinase, kojic acid 
and L-DOPA were purchased from Sigma, India. 
 
4.2.2. Test organisms 
4.2.2.1 Marine fungi 
 
35 fungal strains used in this work were isolated from various marine samples 
collected from west coast and Islands of India (Table 2.2 and Figure 2.3 in Section 
2.3.1) 
4.2.3. Cosmeceutical activity 
4.2.3.1 .Culture extracts 
The method for secondary metabolite extraction of 35 isolated marine fungi was 
described in Chapter 3, Figure 3.2 in Section 3.2.3. 
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4.2.3.2. Anti tyrosinase assay (MBTH assay) 
 
The DOPA oxidase activity of tyrosinase was measured using a colorimetric assay, 
which relies on the oxidation of L-DOPA to dopaquinone, which can be reacted with 
3-methyl-bezothiazolinonehydrazone (MBTH) to form a pink product with peak 
absorbance at 508 nm (Winder, 1994). Briefly, A typical reaction mixture of total 
volume 200 µl contained 120 µl of assay buffer (100 mM potassium phosphate (pH 
6.8), 2% (v/v) N, N‟-dimethylformamide, 5 mM MBTH), 40 µl of mushroom 
tyrosinase (10 unit) and 40 µl of 1.5 mM L-DOPA solution. To study the inhibitory 
effect of fungal crude extracts, 40 µl of crude (5mg/ml) replaced the assay buffer.  
Reaction mixture without enzyme was first incubated at 37°C for 5 min. Enzyme was 
added and the mixture was incubated at 37°C for 10 min; then absorbance was 
measured at 505 nm using a microtiter plate-reader (BioTek, Synergy™ H1). The 
absorbance of the mixture without tyrosinase was used as the control. Kojic acid was 
used as positive controls. The optical density of the inhibition in the control was 
considered to represent 100%. The data are expressed as mean percentages and the 
results were repeated in triplicate. 
 
The % antityrosinase activity was calculated by applying the expression: 
 
 
 
 
 
 
4.2.3.3. Antioxidant assay 
 
Antioxidant activity of the crude extracts was determined by DPPH free radical 
scavenging assay as described by (110) with slight modification. 20 μL of crude 
extract in water was mixed with 180 μL of DPPH in methanol (0.1 mM) in wells of a 
96-well plate. The plate was kept in the dark for 30 min, after which the absorbance 
of the solution was measured at 517 nm in a microtiter plate-reader (BioTek, 
Synergy™ H1). Appropriate blanks (water) and standards (quercetin solutions in 
water) were run simultaneously. Extracts were first tested at a single concentration of 
5 mg/mL, and those showing good evidence of antioxidant activity were tested over a 
range of concentrations.   
 
% Inhibition= (A control − A sample) / A control ×100 
Where A is absorbance at 508 nm 
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The data are expressed as mean percentages and the results were repeated in 
triplicate. 
Inhibition of the DPPH free radical in percentage (I %) was calculated as: 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3.4 Morphological and molecular characterization of potential fungal strains   
 
The method described in Section 3.2.7. 
 
 
4.3. Results  
4.3.1. In vitro depigmenting activity 
In present study, we used the MBTH assay to evaluate the depigmenting activity of 
marine fungal extracts. The data shown in Figure 4.1 indicated that the mushroom 
tyrosinase activity was inhibited by fungal extracts. We observed that at fixed 
concentration (1mg/mL), six strains have shown more than 40% inhibition and five 
strains showed more than 20% inhibition. It was also observed that PDA extracts had 
higher activity then malt extracts. We have selected the eleven most active strains to 
check their activity at different concentrations and found that PDA extracts of P2 and 
D4 strains displayed the highest antityrosinase activity (45%, 43%, respectively) at 
the lowest concentration (0.125mg/mL, Figure 4.2).  
Dose and time dependent anti-tyrosinase activity of crude extracts of the selected 
eleven most active strains were also evaluated. The results indicated that anti-
tyrosinase activity of extracts increased with increasing concentration; however this 
activity decreased over time (Figure 4.3 A, B, C). We hypothesized that either 
enzyme present in the extract degrades the active compound, or crude extract acts 
noncompetitively. The tyrosinase inhibition ability might depend on the hydroxyl 
groups of the phenolic compounds of the fungal extracts that could form a hydrogen 
I % = [(A control − A sample) / A control] ×100  
Where A control is the absorbance of the control reaction (full reaction, 
without the tested extract or quercetin) and A sample was the absorbance 
in the presence of the sample. DPPH solution was prepared freshly. 
Decreased absorbance of the reaction mixture indicates stronger DPPH 
free radical-scavenging activity. 
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bond to the active site of the enzyme, leading to a lower enzymatic activity. Some 
tyrosinase inhibitors act through hydroxyl groups that bind to the active site on 
tyrosinase, resulting in steric hindrance or changed conformation (62). The 
antioxidant activity may also be an important mechanisms for tyrosinase inhibitory 
activity, and so this was also been evaluated. 
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Figure 4.1: (A) Anti tyrosinase activity of Pladi and Dwarka marine fungal crude 
extracts (B) Anti tyrosinase activity of Andaman and Goa marine fungal crude extracts  
 
 
 
 
 
Figure 4.2: Anti tyrosinase activity of eleven selected fungal crude extracts at different 
concentrations 
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Figure 4.3: Dose and time dependent anti tyrosinase activity of eleven selected fungal 
crude extracts 
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4.3.2. Antioxidant activity of fungal extracts  
The scavenging effects of eleven fungal extracts on DPPH radicals increased with 
increasing concentration. At 0.125, 0.25 and 0.50 mg/mL, the scavenging activities 
of extracts on DPPH radical were 55–79, 62–83 and 86–97%, respectively (Figure 
4.4). The results show that the PDA extract of P2 and D4 exhibited the highest 
activity (94%, 97%, respectively) at 0.500 mg/mL, however at 0.125–0.500 mg/mL, 
quercetin showed an excellent scavenging activity of 99–100 percent.  
 
 
Figure 4.4: Scavenging activity of crude extracts of selected fungi against DPPH 
 
4.3.3. Identification of promising marine fungal strains  
A total of 35 fungal strains were isolated and screened for anti-tyrosinase and 
antioxidant activity. The eleven most strongly active marine fungal isolates (P2, P4, 
P8, D4, D6, D25, AN 6/2, AN 10, G 8, G 10, and G15) were selected for further 
study. Of the eleven selected fungal strains the two best (P2 and D4) were selected 
for SEM, sequencing and identification based on ITS sequences. These fungi were 
identified as Talaromyces sp. and Aspergillus sp. respectively (Figure 4.7). Their 
best matches in the NCBI database are shown in Table 4.1, Figure 4.5 and 4.6. 
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Table 4.1: Phylogenetic affiliations of selected fungi with strong activity 
 
Strain Morphological 
identification 
Closest identified relative Access. No. Identity 
(% ) 
P2 Talaromyces sp. Talaromyces stipitatus KJ413383  99 
D4 Aspergillus sp Aspergillus terreus KJ958375 99 
 
 
Figure 4.5: Phylogenetic tree of partial ITS-rDNA sequences of fungal strains  
The evolutionary history was inferred using the Neighbor-Joining method. The optimal tree with the 
sum of branch length = 0.45289971 is shown. The percentage of replicate trees in which the associated 
taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches.  The tree 
is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree.   The evolutionary distances were computed using the Maximum 
Composite Likelihood method and are in the units of the number of base substitutions per site. The 
analysis involved 9 nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. 
All positions containing gaps and missing data were eliminated. There were a total of 328 positions in 
the final dataset. Evolutionary analyses were conducted in MEGA7. 
 
 
 
Figure 4.6:  SEM morphological analysis of sporulating D4 strain 
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4.4. Discussion 
Thirty five (35) fungal strains were selected for this study. Only 2 out of 35 fungi, 
“Fungus P 2” related to T. stipitatus and “Fungus D 4” grouped with A. terreus, 
displayed both strong antityrosinase and antioxidant activities at the lowest 
concentration. Therefore, these two fungi were selected for further study. This is the 
first report of antityrosinase activity from T. stipitatus. 
A. terreus was found to produce an extracellular polysaccharide, YSS, which had 
good antioxidant activity, as determined by its scavenging ability on DPPH radicals 
(150). Two new rubrolides, rubrolides R and S were previously isolated from the 
fermentation broth from A. terreus OUCMDZ-1925. Rubrolide R showed 
comparable antioxidation against 2,20-azino-di(3-ethylbenzthiazoline-6-sulfonic 
acid) (ABTS) radicals to that of trolox and ascorbic acid, with an IC50 value of 1.33 
mM (151). A novel UV-A protecting dipyrroloquinone, terreusinone has been 
isolated from the marine algicolous fungus A. terreus (152). Many other potential 
compounds like sesterterpenoids, terretonins H and I (153), Lumazine containing 
peptides Terrelumamides A and B (154) and terrein (155) were isolated from marine 
A. terreus.  This is the first report of antityrosinase activity from A. terreus.  
4.5. Conclusion 
Inhibitor of tyrosinase is an important class of bioactive compounds, particularly for 
cosmetic use. This study is the first report showing combined antioxidant and 
antityrosinase activities from the marine fungi Talaromyces stipitatus and Aspergillus 
terreus. The results obtained in this study show that compounds present in the 
extracts of Fungus “P2” and “D4” act as inhibitors of mushroom tyrosinase. 
However, they showed lower inhibitory activity than Kojic acid and Quercetin. The 
reducing power of the extracts increased in a dose-dependent manner. Furthermore, 
the fungal culture filtrate extracts inhibited mushroom tyrosinase and decreased 
melanin synthesis in a dose-dependent manner, which may be mediated through its 
antioxidant activity. These extracts and their isolated active compounds have 
potential as and skin whiteners for future cosmeceutical use. 
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Bioassay-guided isolation of antibacterial compounds 
from marine fungus Simplicillum lamellicola 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5 
 
70 
 
5.1. Introduction  
Strain “D5” is a white cottony fungal strain isolated from a marine algal sample 
collected from Dwarka, India. This strain was found to be active against 
Staphylococcus epidermidis bacteria that cause skin microbial infection in humans, 
as reported in chapter 3. This fungal strain was identified as Simplicillium lamellicola 
by morphological and molecular methods. The genus Simplicillium is known to 
produce a variety of compounds but has not been fully chemically characterized.  
A deep sea derived fungal strain Simplicillium obclavatum EIODSF 020 was the 
source of eight new linear peptides, simplicilliumtides A–H. None of the compounds 
showed growth inhibition towards Staphylococcus aureus, Pseudomonas aeruginosa, 
Bacillus amyloliquefaciens, and Bacillus stearothermophilus (156). Chemical 
investigation of the crude extract of a sponge-derived fungus Simplicillium sp. YZ-11 
gave a new minor diketopiperazine alkaloid cyclo-(2-hydroxy-Pro-Gly) and a natural 
lactone (S)-dihydro-5-[(S)- hydroxyphenylmethyl]-2(3H)-furanone. However, no 
activity has been reported for these compounds (157). Three novel mannosyl lipids, 
halymecins F, G and (3R,5R)-3-O-β-D-mannosyl-3,5-dihydrodecanoic acid  were 
isolated from fungus S. lamellicola. These three novel compounds inhibited the 
growth of phytopathogenic bacteria, with halymecin F displaying the strongest 
antibacterial activity (115). A new pyrrolidine alkaloid, Preussin B, was isolated 
from the crude extract of the fungus Simplicillium lanosoniveum TAMA 173. This 
compound showed weak antifungal activity against Saccharomyces cerevisiae with 
an IC50 value of 25 μg/mL (158). A sample of the fungus Simplicillium sp. FKI-5985 
collected from Aogashima, Tokyo, Japan, was the source of Aogacillins A and B. 
Both compounds were displayed antibacterial activity against methicillin-resistant 
Staphylococcus aureus (MRSA) at MIC values of 2.0 μg/mL (159). To the best of 
our knowledge, this is the first report of S. lamellicola from a marine environment.  
This chapter reports bioassay guided isolation of the active component of S. 
lamellicola, using TLC bio autography assay for antibacterial activity. The successful 
isolation of one active biomolecule and establishment of general isolation protocol 
for active metabolites are presented. Identification of the isolated metabolites was 
done using UPLC-MS/MS. 
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5.2. Method and materials 
5.2.1. Chemicals used 
All analytical grade chemicals were purchased from Fischer Scientific (Mumbai, 
India) and used without further purification. PDB and Müller-Hinton agar were 
procured from HiMedia (Mumbai, India) and were sterilized by autoclaving before 
use. 
 
5.2.2. Large scale fermentation and extraction 
S. lamellicola (D5) was maintained on PDA artificial sea water (ASW) at 28°C ± 2, 
pH 7.5. Agar plugs were used to inoculate eight 500 mL Erlenmeyer flasks 
containing 250 mL of PDB in ASW pH 7.5. Flasks were incubated at 28°C ± 1 on a 
rotary shaker at 140 rpm for five days and used as seed culture. Eight 5 L Erlenmeyer 
flasks, each containing 2500 mL of liquid  medium, prepared as above, were 
individually inoculated with 10 % (250 mL) of seed culture and then incubated at 
28°C ± 1 on a rotary shaker at 140 rpm for twenty days. The fermented  broth was 
filtered through cheesecloth to separate the supernatant and mycelia (160). The 
supernatant was passed through an activated Diaion HP-20 resin column (Mitsubishi 
Chemical Co.). Then the column was washed with 500 ml of distilled water and 
finally eluted with 100% methanol until no activity was observed in the collected 
fraction (108). The collected methanol fractions with activity were pooled and 
evaporated, using a Rotary evaporator (BUCHI Rota vapor R-200). The fungal 
mycelia were also soaked in methanol for 24 hours. The methanol layer was 
collected and evaporated to dryness to give a methanol extract of fungal cell biomass, 
which was combined with the above crude extract. The crude extract (6gm) was 
collected and stored in cold condition. 
 
5.2.3. Detection of antibacterial compounds by thin layer chromatography with direct 
bioautography assay 
TLC was performed on aluminium-backed TLC plates (Merck, silica gel 60 F254). A 
suitable mobile phase was standardized based on the separation of antimicrobial 
compounds. TLC was carefully marked and 5 µL of crude extract (5mg/mL in 
methanol) was spotted onto the plate using a glass capillary. A chloroform: methanol 
(9:1) solvent system was used for the separation of active principles. The 
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chromatographic chamber was first saturated with system solvent followed by 
spotting TLC plates for chromatographic separation. TLC strips were dried to 
completely remove traces of the eluting solvents; TLC plates were then observed in 
visible as well as ultraviolet light (365 and 254 nm). The color of resolved bands and 
Rf values were recorded and marked. TLC plates were prepared in duplicate for 
analyzing band separation and bioautography, respectively (161).  
A contact bioautography against S. epidermidis was used (162). Mueller Hinton agar 
no. 2 (HiMedia, India) was prepared and cooled to 40 - 45ºC and bacterial inoculum 
(1.5×108 CFU/mL, 0.5 McFarland), prepared as described in chapter 3, 3.1.2.3,  was 
then added aseptically to the molten agar and poured into sterile petri dishes to give a 
solid plate. Dried and developed TLC plates were then placed on to the media and 
were left for a period of refrigerated for one hour for diffusion. Thereafter, TLC 
plates were removed from the surface with the help of sterile forceps and the plates 
were incubated for 24 hours. The areas of inhibition were marked and checked with 
reference TLC to determine which spot was active. For clear observation and 
photography of inhibition spots dishes were stained with methylthiazolyldiphenyl-
tetrazolium bromide (MTT) (5 mg/mL) solution in water. 
 
5.2.4. Bioassay-guided fractionation of S. lamellicola methanol extract 
Six grams of the dried methanol extract of S. lamellicola D 5 was suspended in 100 
ml of distilled water and partitioned three times with 100 ml of each organic solvent 
in increasing polarity (petroleum ether, hexane, chloroform and ethyl acetate 
(EtOAc). The organic layer was concentrated to yield a solid residue. All organic 
extracts were subjected to TLC bioautography assay against S. epidermidis bacteria.  
The bioactive chloroform fraction 1.3 (500 mg) (Figure 5.1) was then adsorbed onto 
silica gel (5 g) and subjected to column chromatography on silica gel (60 X 20 cm, 
100 g, 60–120 mesh). Elution was achieved using stepwise gradients of 400 mL 
aliquots of each of petroleum ether (100%); – hexane (100%); – hexane:chloroform 
(50: 50) ;– hexane:chloroform (20:80), respectively (Figure 5.1).  Collected tubes 
were subjected to thin layer chromatography (TLC) on silica gel 60F254 plates using 
solvent system chloroform:methanol (80:20). Aliquots with similar TLC profiles 
were pooled to obtain fractions. TLC based antibacterial assay as described above 
showed fraction 1.3.4 was active. Fraction 1.3.4 (180mg) was further subjected to 
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column chromatography on silica gel (60 X 20 cm, 100 g, 200–400 mesh). Elution 
was achieved using solvent gradients of 250 mL aliquots of each of chloroform 
(100%), – chloroform:methanol (99.5:0.5), – chloroform:methanol (99:01), – 
chloroform:methanol (98:02), – chloroform:methanol (95:05) and methanol (100%), 
using a stepwise gradient elution. Aliquots were collected and observed on TLC. 
Aliquots with similar TLC profiles were polled to obtained 7 fractions (1A-7A). All 
were subjected to TLC based antibacterial assay. Fraction 5A showed partial activity 
and 6A showed significant antibacterial activity. Fraction 6A (20mg) was further 
purified using column chromatography on silica gel (60 X 20 cm, 100 g, 200–400 
mesh). Elution was achieved using solvent gradients of 200 mL aliquots of each of 
chloroform (100%), – chloroform:methanol (99.5:0.5), – chloroform:methanol 
(99:01), – chloroform:methanol (98:02), – chloroform:methanol (95:05) and 
methanol (100%) using a stepwise gradient elution. Aliquots were collected and 
observed on TLC. Aliquots with similar TLC profiles were polled to obtain 7 
fractions (6A1-6A7) (Figure 5.2). All were subjected to TLC based antibacterial 
assay. Only fraction 6A5 showed antibacterial activity.  
Isolated pure compound 6A5 and fraction 5A obtained from the previous column 
were subjected to MPLC and UPLC-MS/MS for fingerprinting and identification of 
metabolites.   
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Figure 5.1: Schematic representation of isolation of metabolites from fungi “D5” crude  
extract   
 
 
Figure 5.2: Schematic representation of isolation of active compound from active 
fraction 1.3.4 of “D5” crude extract   
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5.2.5. Identification of isolated antibacterial compound 
5.2.5.1. HPLC analysis  
Identification of active compounds from fraction 5A and 6A5 was done using high-
performance liquid chromatography (HPLC) and LC-MS analysis. Chromatographic 
analysis was performed on a HPLC system (Shimadzu, Kyoto, Japan) equipped with 
a controller (CBM - 20A), quaternary pump (LC- 20AT), solvent degasser system 
(DEU- 20 A5), auto sampler (SIL- 20A) and photo diode array detector (SPDM- 
20A). Inbuilt software (Shimadzu, LC solution) was used to control the HPLC pump 
and acquire the data form the photodiode array. Initial Separations were performed 
with C-18 Phenomenex reverse phase 250 mm column, 5 μm spherical particles and 
10 μl injects at 30 minute intervals was: flow rate 1 ml/min. An isocratic ratio 20:80 
of solvent A (HPLC grade water) and B (HPLC grade C2H3N), respectively, was 
used to elute compounds from the column. The flow rate was 1.0 mL/min, and the 
eluent was monitored at 215 nm.  
 
5.2.5.2. UPLC-mass spectrometry analysis 
Sample 5A and 6A5 was prepared in concentration of 1 mg/ml and subjected to 
UPLC-MS/MS (At Advanced Instrumentation Research Facility (AIRF, JNU, New 
Delhi). UPLC analyses were performed on a Waters Acquity Ultra Performance 
Liquid Chromatographic system with quadrupole mass spectrometer (Waters, 
Milford, MA, USA). To achieve chromatograms with better resolution in a short 
analysis time, the chromatographic conditions were optimized. UPLC separation was 
achieved on an Acquity UPLC BEH C18 column using the mobile phase 0.1% 
formic acid in water (solvent A) and acetonitrile (solvent B) at a flow rate of 0.300 
ml/min; a gradient elution was performed. The total run time was 20 min. The 
injection volume was 5.0 µl. The UPLC system was interfaced with quadrupole mass 
spectrometer (Waters, USA). The same column, elution gradient and flow rate were 
used during the UPLC-MS/MS analysis. Both positive and negative ion modes were 
investigated, and the results showed that higher sensitivities and more information 
were obtained in negative mode. Mass spectrometry was therefore operated in the 
negative ion electrospray mode.  
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5.3. Results and discussions 
This study focused on the identification of antibacterial metabolites produced by the 
marine S. lamellicola and the in vitro activities of these compounds against human 
pathogenic bacteria to identify either novel or lead compounds to synthesize 
derivatives with enhanced activities. The Aogacillins A and B were previously 
identified from a culture broth of terrestrial Simplicillium sp. FKI-5985 with 
antibacterial activity against methicillin-resistant S. aureus (MRSA)(159). However, 
we isolated the strain S. lamellicola from marine habitat. In this study, we have 
characterized previously unidentified antibacterial metabolites produced by marine S. 
lamellicola. 
 
5.3.1. Characterization of substances from the culture broth of marine S. lamellicola 
To reveal the antimicrobial constituents by bioautography, 5 mg/ml of D5 crude 
extract was spotted on TLC. The anti- S. epidermice bioautography of this TLC 
clearly showed that there was at least one or two antibacterial component. The crude 
extract was further fractionated with various solvents. We found that the chloroform 
layer significantly inhibited the growth of S. epidermice and so the material was 
patriated by repeated silica gel column chromatography to provide 7 fractions. Using 
bioassay-guided fractionation, the antibacterial metabolites were isolated from the 6th 
fraction by like normal phase Colum chromatography at atmospheric pressure. 
 
 
Figure 5.3: TLC bioautography of fraction 1.3.4 of “D5” crude extract  
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Figure 5.4 HPLC chromatogram of minor active fraction 5A 
 
Figure 5.5: HPLC chromatogram of purified active compound from fraction 6A5  
 
 
Chapter 5 
 
78 
 
 
Figure 5.6: UPLC-MS chromatograms of minor active fraction 5A 
 
 
 
Figure 5.7: UPLC-MS chromatograms of active fraction 6A5 
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The present study identifies three compounds which were previously reported the be 
isolated from Simplicillium sp. One compound was identified as 5, 6-dihydro-6-
pentyl-5, 6-dihydropyran-2-one, with the molecular formula is C10H18O3 as 
determined by ESI-MS m/z ([M + Cl] -168). Compound 2 identified as simplifungin, 
with molecular formula C18H37NO4 as determined by ESI-MS m/z ([M + Cl]
 - 331). 
Compound 3 was identified as a derivative of halymecin G. Its molecular formula is 
C20H38O6 as determined ESI-MS m/z ([M + Cl] 
-374) (Figure 5.8). The structure 
confirmation of these three compounds by NMR is under investigation and will be 
reported in due course.  
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 Figure 5.8: Structures of compounds identified from marine S. lamellicola 
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5.3.2. Antibacterial activity of pure active compound 
The in vitro antibacterial activity of purified compound 6A5 was tested by direct 
bioautography and caused growth inhibition of S. epidermidis bacteria. This 
compound was identified as 5, 6-dihydro-6-pentyl-5, 6-dihydropyran-2-one. 
 
 
 
Figure 5.9: Fraction 6A5 with moderate antibacterial activity against S. epidermidis  
 
 
5.4. Conclusions  
The active constituent of marine fungus S. lamellicola was isolated and reported in 
this chapter. Fungi “D5” produced one active antibacterial compound, which was 
showed moderate active. Antibacterial bioassay-directed fractionation was used to 
isolate 5, 6-dihydro-6-pentyl-5, 6-dihydropyran-2-one from 6A5 fraction. The 
bioassay of fraction 5A showed minor inhibition. When analyzed the same, a peak at 
Rt 1.198 (of the bioactive compound) was present in the fraction, which could be the 
probable reason of its activity. UPLC-MS/MS data of 5A revealed presence of 
compound “simplifungin” (m/z = 331, [M + Cl] - =368-37). We also propose a 
derivative of previously reported compound “halymecin G” with m/z =374.   
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Widespread application of natural products in many different fields, including 
medicine, food, cosmetics and agriculture has increased the demand for new and 
novel bioactive natural chemical entities. The marine world is a vast resource 
containing structurally complex and novel chemical entities with unique 
pharmacology. The complexity of the marine environment results in the evolution of 
diverse genetically encoded biomolecules with a variety of ecological and metabolic 
roles in marine organisms. The most promising bioactive marine natural products 
have been derived from microbial bioresources such as bacteria, cyanobacteria and 
fungi, particularly as these organisms can be used as production systems for these 
often structurally complex compounds. However marine fungi remain a relatively 
untapped bioresource for bioactive molecules, compared with terrestrial fungi. 
The main goal of the research work described in this thesis was to discover novel 
natural products with cosmeceutical potential by employing targeted 
pharmacological methods. To achieve this goal, the present study describes the 
isolation and identification of some new marine fungi, screening of these fungi for 
bioactive compounds, the isolation and structure elucidation of some bioactive 
secondary metabolites, and some assessment of the pharmacological activity of the 
isolated compounds. Specifically, the antibacterial, antityrosinase and antioxidant 
activities of the marine fungi extracts and purified compounds were assessed.  
 
Chapter 2 describes the occurrence, distribution and diversity of culturable marine 
fungi on various substrata (sea grasses, wood and seaweed) collected at various 
locations in the Indian west coast and Andaman Islands. Effects of nutrient and salt 
concentration on the fungal growth for secondary metabolites production were 
investigated using a range of media conditions. The isolated fungal strains (70 
strains) were maintained on potato dextrose agar in artificial sea water incubated at 
28°C ± 2 for 7-10 days. Individual fungal colonies were picked and checked for 
further purity by sub culturing on potato dextrose agar in artificial sea. Of these, only 
35 strains were culturable and subjected for growth assessment experiments on 
different solid media plate (Media A (PDA in 100% sea water with pH 7.5 (High 
nutrient), Media B (Sea water media (SWM), 1.0% glucose, 0.5% peptone, 0.1% 
yeast extract and 1.7% agar, final pH of 7.5) (Low nutrient), showing a clear 
difference in fungal mycelia growth and spore formation. Higher mycelial production 
was observed in nutrient rich media and earlier spore formation was observed in 
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nutrient deficient media. The results described in this study will be useful for 
selection of growth media and culture conditions for new active fungi for optimised 
production of secondary metabolites.  
 
In chapter 3, the primary aim was to evaluate antibacterial activity of all isolated 
marine fungal strains. Selected strains were further characterized using microscopic 
technique including phase contrast and SEM. A common protocol for secondary   
relatives in the NCBI database, except for one isolates (AN 7). These were 
Simplicillium lamellicola (D 5), Emericellopsis minima (D 6), Leptosphaerulina sp.; 
(AN 7), Penicillium citrinum (AN 10), Aspergillus aculeatus (AN 11), P. 
chrysogenum (AN 12), A. oryzae (G 3) and A. sydowii (G 10).  SEM analysis of the 
targeted bacteria before and after treatment with crude fungal extracts showed that 
the presence of secondary metabolites in the extracts caused damage to bacterial cell 
membrane. Isolate Simplicillium lamellicola (D 5) was the most active extract against 
both Gram-negative and Gram-positive bacteria. This promising strain was 
investigated further using bioassay-guided fractionation for the isolation of bioactive 
compounds. 
 
Chapter 4 describes the effect of selected marine fungi on the pigmentation and 
photoaging of skin. Extracellular secondary metabolites of fungal fermentation were 
concentrated by using Diaion HP20 resin. Here, the first target was inhibition of the 
melanin forming enzyme tyrosinase by the crude extract of each fungal strain. This 
was analyzed using a MBTH assay. The activity of the eleven most active strains was 
investigated over a range of concentrations (0.5-2.0 mg/ml). These extracts were also 
tested for antioxidant activity. Two of the isolates, Talaromyces stipitatus (P2) and 
Aspergillus terreus (D4) were found to have potent activity, comparable with that of 
the positive controls Quercetin and Kojic acid. To date, reports concerning 
antioxidant and antityrosinase metabolites from marine fungi are rare. This study 
demonstrates that marine fungi are a potentially an excellent source for the discovery 
of novel cosmeceutical agents.   
Chapter 5 describes the purification and identification of antibacterial bioactive 
molecules from S. lamellicola extract, via bioassay-guided fractionation using TLC 
bioautography assay. From 20 lit of fermented broth, 6 gm of crude extract was 
prepared by using Diaon HP 20 extraction. Contact bioautography of the extract 
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showed one spot inhibiting activity against Staphylococcus epidermidis bacteria. 
Silica gel column chromatography was performed to purify the active compound 
present in the extract. We isolated one pure active compound, identified as 5, 6-
dihydro-6-pentyl-5, 6-dihydropyran-2-one. One the basis of UPLC-MS/MS data we 
also proposed the presence of the compound “simplifungin” (m/z = 331, [M + Cl] - 
=368-37) and a new derivative of the previously reported compound “halymecin G”, 
with m/z =374.   
 
This thesis is the first report of the isolation of marine S. lamellicola from an Indian 
marine environment and its evaluation for antibacterial activity against a range of 
human pathogenic bacteria.  The antityrosinase activity of Talaromyces stipitatus is 
reported for the first time. Both of these fungi are promising strains for further 
investigation. Future work will target the isolation and identification of antityrosinase 
compounds from T. stipitatus and modification of the identified antibacterial 
compound from S. lamellicola to increase its biological activity. 
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